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ABSTRACT 
LATOYA M. GRIFFIN: Interactions of Antiretroviral Protease Inhibitors with 
Hepatic Transport Proteins: Mechanisms of Drug-induced Liver Injury 
 (Under the direction of Dr. Kim L. R. Brouwer) 
 
 Lopinavir and ritonavir are protease inhibitors available as a coformulation 
for the management of HIV infection.  However, liver enzyme elevations are 
associated with protease inhibitor use.  Inhibition of bile acid transport leading to 
cellular accumulation of bile acids is one proposed mechanism of drug-induced 
liver injury (DILI).  The global objective of this project was to investigate the 
influence of coadministered protease inhibitors on the hepatobiliary disposition of 
bile acids.  Canalicular excretion of bile acid transport is facilitated by the bile salt 
export pump (BSEP).  Impaired BSEP activity is a risk factor in the development 
of DILI.  Drugs that decrease BSEP function are considered liver liabilities from a 
drug development perspective.  Potent inhibitory activity of lopinavir and ritonavir 
in vitro has been demonstrated previously.  However, the combined effect of 
lopinavir and ritonavir on the hepatobiliary disposition of bile acids has not been 
determined.  Experiments were undertaken to determine the consequences of 
coadministered lopinavir and ritonavir on hepatocellular viability and bile acid 
transport.  Lopinavir, alone and combined with ritonavir, demonstrated minimal 
toxicity but inhibited the biliary excretion of taurocholate and chenodeoxycholate 
in sandwich-cultured rat hepatocytes (SCRH).  Studies in suspended rat 
hepatocytes revealed that neither lopinavir nor ritonavir altered the initial uptake 
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of either bile acid.  Contrary to expectations, 24-hour exposure to lopinavir and 
ritonavir significantly decreased measured endogenous bile acid concentrations 
in SCRH.  Lastly a genetic association study was carried out to explore the 
relationship between genetic variants in genes involved in bile acid transport or 
metabolism and risk of DILI.  A comparison of data from patients in the Drug-
induced Liver Injury Network to controls obtained from the British Birth Cohort 
revealed a significant association between the rs2919351 variant in OSTß and 
susceptibility to cholestatic and mixed liver injury.  This work demonstrates that 
10-minute lopinavir and ritonavir exposure, alone and combined, significantly 
impaired the biliary excretion of exogenously administered bile acids.  However, 
24-hour exposure to lopinavir and ritonavir evoked little toxicity in vitro.  The lack 
of toxicity may be due to protective mechanisms in normal-functioning 
hepatocytes, such as a decrease in both the synthesis and cellular retention of 
endogenous bile acids. 
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CHAPTER 1 
INTRODUCTION 
Membrane transport proteins facilitate the absorption, distribution and 
elimination of numerous xenobiotics and endogenous compounds in humans.  
Consequently, transporters may be important determinants of the pharmacokinetic 
disposition and ultimately, the efficacy and safety of therapeutic agents.  Many 
studies in knock-out rodent models and humans with loss-of-function genetic 
variants have demonstrated substantial changes in bioavailability, virologic 
resistance, and adverse drug reactions.  These findings highlight the significance of 
drug-transporter interactions.  Additionally, emerging studies in both humans and in 
vitro models (e.g. freshly isolated hepatocytes) support the hypothesis that impaired 
bile acid transport increases the risk of drug-induced liver injury (DILI).  
 
1Liver toxicity is a common adverse event associated with the use of 
antiretroviral protease inhibitors (PIs).  Interestingly, the pharmacokinetic profile of 
PIs is highly variable, making it difficult to predict the risk of the development of 
hepatotoxicity in patients.  Inhibition of the bile salt efflux pump (BSEP) leading to 
the cellular accumulation of bile acids has been shown for PIs.    In an effort to better 
predict the risk of cholestasis, few clinical studies have attempted to characterize the 
                                                 
This chapter is published, in part, in Journal of Pharmaceutical Sciences. Griffin, L., Annaert P., 
Brouwer K.L. 2011 Sep;100(9):3636-54. 
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relationship between antiretroviral therapy and plasma concentrations of bile acids 
however, the link remains unclear.  Understanding the role of transport proteins in 
the overall disposition of drugs and/or bile acids is required to individualize drug 
therapy and improve health outcomes.  The first section of this chapter highlights 
clinically significant interactions of transporters with PIs.  The second and third 
sections discuss toxicity associated with PI therapy and regulation of bile acid 
synthesis and transport.  The final portion of this introductory chapter provides a 
brief overview of in vitro tools currently employed to evaluate interactions between 
drugs, endogenous compounds, and transport proteins. 
 
PART I. Influence of Drug Transport on Pharmacokinetics and Drug 
Interactions of HIV Protease Inhibitors 
Saquinavir was the first PI introduced to the U.S. market in 1995 for the 
treatment of HIV/AIDS.1 This class of life-saving antiretroviral agents has expanded 
to now include eight PIs that play an important role in the management of HIV 
infection.2 Currently, the most frequently prescribed HIV PIs include lopinavir, 
atazanavir, darunavir and fosamprenavir, each of which is typically used in 
combination with one or more Nucleoside Reverse Transcriptase Inhibitor (NRTI) in 
Highly Active Antiretroviral Therapy (HAART) regimens.3 In addition, more recent 
clinical data support the potential utility of HIV PI monotherapy in patients with 
prolonged viral suppression on HAART,4 further illustrating the unique efficacy 
profile of these antiretroviral agents. The spectacular improvements in treatment 
success and life expectancy in patients with HIV infection can be attributed, in part, 
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to the long-term suppression of HIV replication by antiretroviral regimens with 
acceptable side-effect profiles.5 HIV PIs currently are key components of first-line 
therapy in both treatment-naive and -experienced patients. A major challenge in 
antiretroviral pharmacotherapy is the potential for gradual development of viral 
resistance. The introduction of 2nd generation PIs such as darunavir, which require at 
least four concomitant mutations in the viral genome for resistance development, 
has provided clinicians with superior drugs to counter the development of 
resistance.6  
   Physicochemical properties of the HIV PIs are summarized in Table 1.1. In 
general, HIV PIs are peptidomimetic, large molecular weight, and often poorly water 
soluble compounds.  Consistent with their physicochemical properties, HIV PIs tend 
to be highly protein bound and extensively metabolized by cytochrome P450 (CYP) 
3A4 (Table 1.8), with relatively short terminal elimination half-lives in plasma. Long-
term therapeutic success can be maintained only when minimum trough 
concentrations of the HIV PIs are achieved.4 Rapid elimination from plasma requires 
multiple daily doses of HIV PIs to maintain therapeutic concentrations, which 
complicates patient adherence to therapy. Ritonavir is a remarkably potent 
mechanism-based inhibitor of CYP3A4. Concomitant administration of a 
subtherapeutic dose (100-200 mg) of ritonavir as a pharmacokinetic booster 
(“enhancer”) together with HIV PIs increases exposure of lopinavir, atazanavir and 
darunavir several-fold.7  The use of ritonavir as a “boosting” agent was a major 
advance in HIV PI-based therapy,8,9 and has led to the development and marketing 
of once-daily dosage forms of HIV PIs, which has significantly increased patient 
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adherence. In addition, the clinical use of ritonavir-boosted HIV PIs has improved the 
side-effect and toxicity profile of HAART regimens.10 For example, the addition of 
ritonavir to atazanavir-based dosing regimens resulted in decreased incidence of 
lipoatrophy as compared to unboosted treatments.11 
Although the clinical strategy of using ritonavir as a boosting agent has 
enhanced the success of HIV PI-based antiretroviral regimens, it also has resulted in 
increased potential for drug-drug interactions (DDIs).12 Drugs metabolized by 
CYP3A4 exhibit much longer elimination half-lives in ritonavir-treated patients as 
compared to other patients. Additional levels of complexity with respect to DDI 
potential are encountered in patients co-infected with M. tuberculosis, an infection 
that is increasing in prevalence in resource-limited countries.13 Successful 
eradication of tuberculosis almost always requires administration of the very potent 
CYP3A4-inducer rifampicin, or the less potent but more expensive inducer rifabutin.  
These drugs reduce exposure to ritonavir-boosted HIV PIs.  
Hepatic metabolism is an important step in the systemic elimination of HIV 
PIs. Importantly, drug transporters also play a key role in the oral bioavailability, 
hepatobiliary elimination and distribution of HIV PIs to target (lymphocytes) and 
peripheral (brain) tissues. The recent approval of PIs for the treatment of hepatitis C 
has increased the number of patients who are exposed to this class of drugs, and 
emphasizes the importance of understanding factors that influence their 
pharmacokinetics and DDI potential. 
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The Impact of Transporters on Protease Inhibitor Pharmacokinetics/ 
Pharmacodynamics. Pharmacological and toxicological effects of PIs are 
determined by drug absorption and distribution which are influenced by transporter-
mediated processes.  Thus, identifying transport proteins that interact with PIs and 
understanding the magnitude of their contribution to overall drug disposition is 
critical.  Although PIs are known to inhibit active transport processes, data regarding 
the ability of PIs, themselves, to act as substrates for uptake proteins remains 
controversial.  Significant temperature-dependent uptake of ritonavir, saquinavir and 
nelfinavir into suspended rat hepatocytes, indicative of active uptake processes, has 
been reported.14  In addition to evidence provided by limited in vitro studies, the 
physicochemical properties of PIs (e.g., molecular size, protein binding, and 
lipophilicity) also should be considered.  Localization and orientation of membrane 
transporters in a generalized cell is illustrated in Figure 1.1.  Transporters have 
been well characterized in the liver, kidney and, to a lesser extent, the brain and 
intestine.  Unfortunately, one challenge in the field is that the expression, localization 
and functional activity of transport proteins at target sites for viral transmission and 
sequestration, including the testicular system, female genital tract, lymphocytes and 
placenta are poorly characterized.  However, this lapse in scientific knowledge is 
appreciated and studies in this area are ongoing.  For an in depth discussion of the 
interactions between antiretroviral agents and transporters at these relevant organ 
systems see Kis et al. 2010.15   The following discussion serves as an overview of 
solute carrier (SLC) and ATP-binding cassette (ABC) membrane transport proteins 
involved in the uptake and efflux of PIs known to date.  
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 Impact of SLC Transporters on Protease Inhibitor 
Pharmacokinetics/Pharmacodynamics. Transporter-mediated uptake, largely 
governed by members of the SLC superfamily, may be rate limiting in the oral 
bioavailability and hepatobiliary clearance of drugs.  The most prominent transporter 
interactions with PIs involve the organic anion transporting polypeptides (OATPs) 
and organic cation transporters (OCTs); the clinical relevance of these interactions 
has been well documented. 
 
OATPs 
OATPs, which are expressed in numerous organs and tissues including the 
intestine, liver, kidney, and placenta, mediate the sodium-independent bidirectional 
transport of diverse substrates including bile acids, bilirubin and xenobiotics.16,17 
OATPs interact with several PIs in vitro.  OATP1A2, -1B1 and -1B3 expressed in 
Xenopus laevis oocytes mediate the uptake of lopinavir and saquinavir.18-20  
Darunavir transport via OATP1A2- and -1B1- also has been reported.19,20  Lopinavir, 
atazanavir, darunavir, ritonavir, and saquinavir inhibit OATP1B1- and -1B3-mediated 
CGamF accumulation in chinese hamster ovary (CHO) cells.  Inhibition of 
OATP2B1-mediated transport of estrone 3-sulfate by atazanavir, lopinavir, tipranavir, 
nelfinavir, indinavir, saquinavir, and ritonavir also has been shown in Caco-2 
cells.21,22 The clinical implications of these interactions are evident, for example, in 
the significant association between the OATP1B1 521T>C polymorphisms and 
elevated lopinavir plasma concentrations.19 Additionally, a recent pharmacogenetics 
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study revealed that variability in lopinavir clearance was impacted by both genetic 
variants in OATP1B1 and ritonavir plasma concentrations.23  
 
OCTs  
OCTs, which are located predominantly in the kidneys and liver, are 
electrogenic uniporters that primarily transport small cations in a sodium-
independent manner.  Transport of uncharged and anionic compounds such as 
prostaglandins by OCTs has been described.24 OCT1 and OCT3 are expressed at 
the sinusoidal membrane of liver tissue.  OCT1 is expressed exclusively in the liver 
while OCT3 has a broader range of tissue distribution.  Nelfinavir, ritonavir, indinavir, 
and saquinavir are reportedly potent inhibitors, but poor substrates, of OCT1- and 
OCT2-mediated transport.25,26  Though the contribution of OCTs to PI transport 
remains unclear, several nucleoside NRTIs are translocated by OCTs and often are 
coadministered with PIs, increasing the risk of DDIs. 
 
The Impact of ABC Transporters on Protease Inhibitor 
Pharmacokinetics/Pharmacodynamics. Members of the ABC transporter 
superfamily comprise one of the largest protein families with representatives in all 
living organisms.  The structure and function of ABC transporters are relatively 
conserved across species. ABC transporters facilitate the transmembrane 
movement of substrates by utilizing the energy generated by ATP hydrolysis.27 
Mounting evidence suggests that ABC transport proteins confer drug resistance and 
alter PI pharmacokinetics/pharmacodynamics by decreasing bioavailability, 
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promoting sequestration at sanctuary sites, and decreasing accumulation in target 
organs and tissues.28 This review focuses solely on ABC transporters clinically 
shown to impact the disposition of PIs.   
 
P-gp 
P-glycoprotein (P-gp; MDR1), which is expressed ubiquitously, protects cells 
from the accumulation of toxic drugs, metabolites, and endogenous compounds. P-
gp exhibits broad substrate specificity, including PIs. Expression of P-gp in the 
intestine, brain and blood-testis barrier alters oral bioavailability and intracellular 
concentrations of PIs in vivo.29-31 P-gp-mediated efflux of all currently marketed PIs 
has been demonstrated in several in vitro systems, including Caco-2 and MDCK-II 
cells.32-36  Ritonavir, lopinavir, and nelfinavir also inhibit P-gp-dependent efflux of 
calcein-AM in MDCK-II cells.37 In addition to inhibition of P-gp transport, saquinavir 
and darunavir induce P-gp mRNA expression and activity in vitro. Induction by 
darunavir increased cellular resistance, as measured by growth inhibition assays in 
LS-180 cell lines.38   
 
BCRP 
Breast cancer resistance protein (BCRP) is expressed in the liver, kidney, 
testis, GI tract and a many other tissues.  BCRP is responsible for the extrusion of a 
broad range of both endogenous and exogenous compounds.  Many PIs including 
lopinavir, nelfinavir, saquinavir, and ritonavir are effective inhibitors of BCRP-
mediated transport, but appear to be poor substrates in vitro.39-41  Although BCRP-
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mediated transport of PIs has not been elucidated, BCRP activity is known to alter 
systemic and tissue concentrations of a antiretrovirals and in particular, PIs.42 
Consequently, the likelihood of DDIs between PIs and BCRP substrates remains a 
concern. 
MRPs 
To date, there are nine members of the multi-drug resistance-associated 
protein (MRP) transporter family.  MRPs 1-5, all organic anion pumps, have been 
studied most extensively.  MRP1 and MRP2 have similar substrate specificities; 
however, localization and tissue distribution differ. MRP1 is expressed widely and 
located in the basolateral membrane, while MRP2 is localized on the apical 
membrane and its expression is restricted primarily to the liver, kidney, and intestine.  
MRP3 is expressed on the basolateral membrane of the liver, kidney and 
gastrointestinal tract.29,43 Common MRP1, MRP2, and MRP4 substrates include 
glutathione conjugates and anionic drugs. Bilirubin glucuronide is a substrate for 
both MRP2 and MRP3.44,45 MRP2-mediated transport of saquinavir, ritonavir, 
indinavir, and lopinavir has been shown in stably transfected human MDCK-II 
cells.32,46 Saquinavir, ritonavir, and atazanavir potently inhibit MRP2-mediated biliary 
efflux of CDF in human hepatocytes.47 In a panel of ABC transporter over-
expressing cell lines, atazanavir, lopinavir, and ritonavir inhibited MRP1 activity.39 
Furthermore, treatment with darunavir/ritonavir induced MRP1 protein expression in 
CD4 (+) T-cells from healthy human volunteers. MRP1-mediated efflux of 
carboxyfluorescein diacetate increased upon co-administration with efavirenz.48 The 
contribution of MRPs to the transport of PIs remains unclear. 
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Drug-drug Interactions Involving Transporters and HIV Protease 
Inhibitors.  Numerous in vitro and in vivo studies have demonstrated that most HIV 
PIs interact with both CYP3A4 and P-gp, either as a substrate, inhibitor or 
inducer.8,49,50 Given the dominant roles of these proteins in drug disposition, most 
clinical DDI studies have focused on the contribution of CYP3A4 and/or P-gp.8 In 
addition to the CYP3A4-mediated inhibition of PIs by ritonavir, a beneficial DDI that 
is utilized chemically in HAART regimens, synergistic effects have been observed 
with other combinations of HIV PIs.  Dam and co-workers suggested that the 
synergistic inhibition of HIV-1 by a combination of saquinavir with lopinavir or 
atazanavir could be explained, at least in part, by enhanced inhibition of efflux 
mechanisms from target cells.51 The complexity of HIV PI-based treatment 
regimens, often in combination with non-antiretroviral medication (e.g. anti-
tuberculosis drugs), increases the potential for clinically significant DDIs (see 
www.hiv-druginteractions.org for a summary of risks and severity of antiretroviral 
DDIs). Unfortunately, details regarding the underlying mechanisms responsible for 
these DDIs are lacking, but clearly extend far beyond the involvement of CYP3A4 
and P-gp. Clinically relevant changes in PI concentrations often may be the net 
result of multiple DDIs that have opposite effects (e.g. concomitant induction and 
inhibition); the outcome frequently depends on the exact dose and regimen (e.g. 
etravirine and darunavir/ritonavir in Table 1.2).52 Another reason for the lack of 
mechanistic information is that the relative roles of drug metabolizing enzymes and 
transporters in drug disposition and DDIs remain poorly understood. Tables 1.2 and 
1.3 provide a summary of clinically relevant DDIs involving HIV PIs and drug 
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transporters; specific DDIs involving HIV PIs as ‘perpetrator’ drugs (Table 1.2), and 
those mediated by HIV PIs as ‘victim’ drugs (Table 1.3), are discussed below.  
 
Mechanisms of HIV Protease Inhibitor DDIs: Drug Transporter Inhibition. 
HIV PIs are both substrates and potent inhibitors of some SLC and ABC transport 
proteins, and typically behave as perpetrators when considering DDIs elicited by 
transporter inhibition.  In addition, when more than two HIV PIs are combined, 
different PIs can act as the perpetrator and victim. This is illustrated by the effect of 
atazanavir on the pharmacokinetics of saquinavir when coadministered with 
ritonavir.53 Saturation and/or inhibition of efflux transporters modulating HIV PI 
accumulation may explain this interaction.  
The most well documented DDIs with respect to transporter inhibition involve 
HIV PIs and the disposition of well-known P-gp substrates including digoxin, 
fexofenadine, and loperamide. For example, single or multiple dose regimens with 
indinavir/ritonavir increased fexofenadine plasma AUC up to 5- and 4.2-fold, 
respectively.54 The most pronounced effects on digoxin exposure were reported after 
300 mg bid ritonavir or 400/100 mg lopinavir/ritonavir in combination with 
intravenous or oral digoxin doses of 0.5 mg.55 Loperamide exposure was increased 
more than 3-fold in the presence of 600 mg ritonavir.56 Case reports of elevated 
tacrolimus or sirolimus concentrations when combined with ritonavir-boosted 
amprenavir or darunavir also support pronounced P-gp inhibition.57,58 HIV PIs 
appear to exhibit much less pronounced (up to 37% increase) effects on the plasma 
exposure of the NRTI and P-gp substrate tenofovir following co-administration of the 
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disoproxil fumarate prodrug of tenofovir.59 Minor increases in tenofovir plasma AUC 
values were observed, which were attributed to inhibition of P-gp mediated intestinal 
efflux of the prodrug.59,60 
Compared to ABC transporter-based DDIs, much less is known about the 
potential role of HIV PIs in DDIs associated with uptake transporters. Limited data 
suggest that hepatic uptake transporters of the SLC family (specifically OATP1B1 
and OATP1B3) are likely to play key roles in some DDIs involving HIV PIs. Shitara 
recently reviewed current clinical evidence demonstrating substantial alterations in 
the pharmacokinetics of OATP1B1 substrates (i.e. statins, repaglinide, and 
bosentan) in combination with the OATP1B1 inhibitor cyclosporin A. These data 
revealed increases in the AUC of atorvastatin of up to 9-fold.61 Pronounced 
increases in the AUC of the lipid-lowering drugs atorvastatin and rosuvastatin have 
been reported with coadministration of boosted lopinavir and tipranavir; OATP1B1 
inhibition has been suggested as a likely mechanism to explain this interaction.62  
Moderately decreased exposure to the NRTI elvucitabine when combined with a 
single 300 mg ritonavir dose may be attributed to ritonavir-mediated inhibition of 
intestinal uptake transporters.63 
Finally, it is noteworthy that even though pronounced species differences 
exist,47 several animal studies also support the role of transporters in mediating DDIs 
involving HIV PIs. For example, ritonavir enhanced darunavir absorption via P-gp 
inhibition in mouse in situ intestinal perfusions.64  
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Mechanisms of HIV Protease Inhibitor DDIs: Drug Transporter Induction. 
Data obtained in various in vitro models have shown that HIV PIs show affinity for 
the pregnane X receptor (PXR), activation of which is clearly linked to regulation of 
drug metabolizing enzymes as well as drug transporter expression.65,66 Induction of 
drug metabolizing enzymes by HIV PIs is a common mechanism underlying clinically 
relevant PI-associated DDIs.67,68 Much less information is available with respect to 
the exact role of altered expression of drug transporters and changes in the 
pharmacokinetics of coadministered drugs relying on those drug transporters. 
Nevertheless, numerous examples in Table 1.6 illustrate that most drug transporters 
are susceptible to the inducing effects of HIV PIs. Clinically relevant DDIs that may 
be attributed, at least in part, to HIV PI-mediated up-regulation of P-gp activity are 
included in Table 1.2. For example, there is a 2-3-fold decrease in loperamide 
exposure when combined with tipranavir/ritonavir (TPV/r).69 The latter PI 
combination also significantly reduced exposure to the P-gp substrate digoxin, 
presumably through induction of P-gp, following concomitant doses of TPV/r.70  It 
should be noted that the inducing effects of tipranavir predominate in contrast to 
ritonavir, which primarily inhibits P-gp when combined with loperamide or digoxin. 
The 25% reductions in fexofenadine Cmax and half-life when combined with nelfinavir 
for 1 week, may be explained by induction of intestinal P-gp and/or hepatic OATPs.71  
The reduced exposure to delaviridine also could be due to induction of P-gp by 
amprenavir.72 The NNRTI etravirine can be combined with several boosted PIs, 
including darunavir, lopinavir, and saquinavir;73 however, when combined with 
TPV/r, the plasma exposure of etravirine is decreased by 76%.  As etravirine is not a 
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P-gp, BCRP or MRP substrate,74,75 induction of uptake transporters (e.g. OATPs) by 
tipranavir and/or ritonavir (in addition to induction of drug metabolizing enzymes) 
may contribute to this interaction. 
Combined use of rifampicin, an anti-tuberculosis agent and potent inducer of 
drug metabolizing enzymes and transporters, with antiretroviral medication including 
HIV PIs is of high clinical relevance. As outlined in Table 1.3, reductions in HIV PI 
exposure when combined with rifampicin range from 75% to 89%, even in the 
presence of ritonavir as a boosting agent. When different LPV/r regimens combined 
with rifampicin were evaluated by La Porte et al., LPV/r combinations with higher 
ritonavir dose levels (i.e. LPV/r 400/400 > LPV/r 800/200) appeared to provide better 
compensation for the inducing effects of rifampicin.76  This was especially reflected 
in the Cmin concentrations achieved with the LPV/r 400/400 dose regimen, which 
tended to be comparable to the Cmin concentrations achieved with the reference 
treatment of LPV/r 400/100 in the absence of rifampicin. Therefore, the use of 
rifabutin rather than rifampicin in the management of M. tuberculosis infection in HIV 
positive patients on antiretroviral therapy is highly recommended. 
 
Transporter-mediated Processes Underlying Toxicity of HIV PIs. Both 
endogenous and exogenous (e.g. drugs) compounds are substrates for transporters.  
Interference of drugs with endogenous substrate transport may constitute a 
mechanism of drug-mediated toxicity. For example, interference of certain drugs 
(e.g. bosentan, troglitazone) with hepatic bile salt transport has been implicated as 
one mechanism in the development of drug-induced cholestasis.77  Several HIV PIs 
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have been shown to interact with bile salt disposition in human and rat 
hepatocytes,78 and this may explain, at least in part, the hepatotoxicity observed in 
some patients taking HIV PIs.79 Rotger et al. quantified the effect of HIV PI-
containing antiretroviral therapy on the incidence of hyperbilirubinemia in 96 HIV-
infected patients. Atazanavir and indinavir (but not lopinavir, saquinavir, ritonavir, 
and nelfinavir) exhibited an increased incidence of elevated serum bilirubin 
concentrations.80 Inhibition of the bilirubin conjugating enzyme UGT1A1 by these PIs 
has been proposed as a potential mechanism underlying this interaction. However, 
in vitro data generated by Campbell et al.81 and Ye et al.47 also support potent 
inhibition of OATP1B3, the bilirubin-transporter, by indinavir and atazanavir. As 
noted in Table 1.7, the altered lipid metabolism associated with HIV PI-based 
therapy may be caused by inhibition of transport of the endogenous substrate 
palmitate.82 
 
Influence of HIV Infection, Co-infection and Antiretroviral Therapy on 
Transporters: Implications for Protease Inhibitor Pharmacokinetics/ 
Pharmacodynamics. The effect of HIV infection on transporter expression and 
activity is not well understood.  Effects of diseases on P-gp mRNA expression and 
activity have been studied more extensively than other transport proteins. P-gp 
mRNA expression was decreased in leukocytes and PBMCs of SHIV infected 
macaques; changes in expression were more pronounced in animals receiving 
antiretroviral treatment that included indinavir.  However, indinavir decreased P-gp 
expression, making it difficult to determine whether the disease state or indinavir 
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itself were responsible for the observed effects;83 similar findings have been reported 
in humans.  Lucia and colleagues reported that P-gp function in peripheral blood 
lymphocytes, as measured by rhodamine-123 efflux, was decreased in HIV-infected 
patients.  Separate clinical studies in patients with HIV infection relative to healthy 
volunteers support these findings, although expression of MRP1 in PBMCs was not 
altered.84 Increased MRP-mediated efflux also has been reported in patients with 
primary HIV infection that strongly correlates with disease progression.85  In contrast, 
a time-dependent significant increase in P-gp expression in PBMCs from HIV+ 
individuals has been reported.86 
The influence of hepatitis C co-infection on transporter function, and the 
potential implications for antiretroviral therapy, has been the subject of recent 
investigations due to the increasing prevalence of co-infection.  MRP4 protein 
expression is induced in patients with cholestasis and animals with common bile 
duct ligation. These changes may facilitate compensatory MRP4-mediated 
basolateral efflux of endogenous compounds such as bile acids.87-90 MRP2 mRNA 
levels also are significantly decreased in human HCV-infected liver tissue relative to 
non-infected tissue.91 In addition, significant reductions in OCT1 and OATP1B1 
mRNA which correlated with hepatitis C progression also have been reported in 
humans.92   
MRP1 expression in total human lymphocytes is unaffected by atazanavir 
treatment, but increased in human brain microvascular endothelial cells (HBMECs).  
P-gp expression, however, was increased in both total lymphocytes and HBMECs.93 
In human PBMCs, efavirenz-mediated induction of MRP1 and MRP6 mRNA has 
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been reported.  Tenofovir also was associated with a reduction in P-gp, MRP1, 
MRP5, and MRP6 mRNA expression in humans.94  
Regulation of transporter expression by nuclear receptors such as PXR and 
CAR is now well-established.  For example, induction of P-gp and MRP1 by 
ritonavir, and P-gp by saquinavir, both PXR agonists, has been reported.95-97  
Although a reduction in MRP1 protein expression in PBMCs of healthy volunteers 
following administration of darunavir/ritonavir was observed, the clinically relevant 
consequences of these changes remain unclear.48 
Also, proinflammatory cytokines TNF-α, IL-1ß, and IL-6 are reportedly 
increased in HIV-infected patients and have been shown to modulate key 
transporters in vitro.98-100 For example, all three aforementioned cytokines decreased 
MRP2 mRNA and protein expression in sandwich-cultured human hepatocytes.  In 
the same study, IL-6 and IL-1ß BSEP mRNA expression was decreased while 
protein levels were increased.99  NTCP, OCT1, OCT2, OATP1B1, -1B3, and -2B1 
mRNA levels following 48-hour exposure to TNF-α or IL-6 were decreased. In 
addition, P-gp, MRP2, and BCRP mRNA were also reportedly decreased by IL-6. 
TNF-α also decreased BSEP mRNA and, conversely, increased BCRP and MRP3 
protein expression levels.100 Initiation of antiretroviral therapy is associated with a 
reduction in proinflammatory cytokine levels.101 Cervia and colleagues report 
significantly decreased TNF-α and a nonsignificant trend towards reduced IL-6 in 
HIV-infected children initiating or changing antiretroviral therapeutic regimens.98   
Evidence in the literature demonstrating a direct effect of HIV infection, co-
infection and HAART therapy on transporter phenotype and function remains limited 
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and controversial for a number of reasons.  The contribution of HIV infection, 
underlying symptoms, co-infection and antiretroviral therapy to pathophysiological 
changes are multifactorial and difficult to distinguish. In addition, appropriate models 
to investigate the intricate relationships are limited.  The effect of HIV infection and 
co-infection on transporter function is the subject of ongoing investigations.  
HIV PIs that interact with transport proteins are likely candidates for DDIs 
resulting in toxicity or the development of cellular resistance.  Consequently, 
chemotherapeutic agents that exhibit minimal interactions with transport proteins 
such as P-gp are preferred.102 Conversely, therapeutic agents that competitively 
inhibit transporters governing efflux may increase victim drug concentrations in 
relevant organs and tissues (e.g. lymphocytes), thereby enhancing efficacy and 
decreasing pill burden.   For example, Pluronic P85, an amphiphilic block copolymer 
and P-gp inhibitor, increases saquinavir and nelfinavir accumulation in MDCKII-
MDR1 cells.103 Modulation of transport function is particularly promising given the 
difficulty of antiretrovirals to penetrate sites of viral sequestration, such as the brain, 
which expresses a number of efflux transporters known to interact with PIs, including 
P-gp, BCRP, and MRPs.104-106 In addition to transporter interactions, HIV PIs may 
interact with cytochrome P450s, modify posttranscriptional regulation of nuclear 
receptors, and alter bile acid biosynthesis and metabolism.  Gender, genetic 
polymorphisms and lifestyle choices such as smoking and alcohol consumption also 
must be taken into consideration when trying to predict the likelihood of drug-
transporter interactions.  Toxicity and efficacy associated with these interactions is 
undoubtedly multifactorial and remains difficult to predict.  However clinicians, 
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scientists and regulatory agencies are becoming increasingly aware of the 
importance of understanding the dynamics of these relationships and are working 
together to ensure the emergence of safe and efficacious chemotherapeutic 
treatment options.  
 
PART II.  Hepatotoxicity Associated with Lopinavir and Ritonavir  
LPV is only marketed in combination with RTV as a fixed-dose co-formulation 
under the tradename Kaletra®.  LPV combined with RTV has become a front-line 
therapy in the treatment and management of HIV-1 infection.  Despite the success of 
antiretroviral treatment, PI-associated hepatotoxicity, defined as > 5 times the upper 
limit of normal ALT or AST levels, may necessitate discontinuation of therapy and, 
consequently, virologic failure.107  An accurate assessment of the incidence of PI-
related hepatotoxicity in humans is difficult to establish due to limitations in study 
designs including patient inclusion/exclusion criteria, comorbidities, concomitant 
medications, and limited follow up. Although the results of studies combining data 
from multiple cohorts and databases continue to emerge, inconsistent definitions of 
liver toxicity and variability in patient populations often consisting of co-infected 
patients on numerous non-ARV drugs confound the interpretation of data.108 
 Unfortunately, mechanisms of liver toxicity related to PI exposure are poorly 
understood.   The idiosyncratic nature of PI-induced hepatotoxicity makes prediction 
of adverse events in patients challenging.  Growing evidence suggests that several 
factors increase the risk of hepatotoxicity in PI-treated patients including hepatitis B 
or hepatitis C co-infection, baseline liver function tests, length of drug therapy, and 
 20 
 
gender (females exhibit a higher incidence than males). In an open, prospective, 
observational study conducted by Meraviglia and colleagues, 9.1% of patients 
treated with LPV/r developed liver enzyme elevations within the first 115 + 85 days 
of initiating treatment.  Of these patients, ~75% and 25% exhibited grades 2 and > 3 
toxicity, respectively.109 In a one-year observational study conducted by Bongiovanni 
et al., hepatitis C co-infected patients treated with PI-containing HAART regimens 
exhibited a 7.4-fold greater risk of discontinuing LPV/r therapy due to drug-related 
adverse events, including liver toxicity.  Additionally, high dose RTV has been 
identified as a risk factor for patients on ARV therapy.110  RTV is now coadministered 
primarily at subtherapeutic doses in combination with other PIs to enhance their 
systemic concentrations.  Thus, clinical reports of liver toxicity directly associated 
with high dose RTV has decreased over the years. 
 The pathogenesis of PI-associated liver injury remains unclear.  One 
proposed mechanism is immune-mediated hypersensitivity in which the  immune 
system’s recognition of potential viral pathogens is restored following the successful 
initiation of HAART therapy, after which fulminant viral hepatitis ensues.111   Harrill et 
al. reports an association between polymorphisms in the CD44 gene and high serum 
ALT levels after acetaminophen exposure in two separate patient cohorts.  This 
gene encodes the CD44 antigen which is involved in an array of cellular functions 
including lymphocyte activation and tumor metastasis.  Thus, differences in genes 
associated with the innate immune response may contribute to the variability in 
pharmacologic and toxicologic responses to drugs.  
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The liver is the principal site of metabolism for PIs.  Another potential 
mechanism of PI-induced liver injury is that disturbances in metabolic pathways may 
cause an accumulation of parent compound and/or reactive metabolites, ultimately 
producing mitochondrial dysfunction.  A recent review by Tuijos and colleagues 
highlights mitochondrial toxicity, typified by the deposition and accumulation of fat in 
hepatocytes, associated with a number of drugs including amiodarone and 
valproate.112  The discovery that antiviral nucleoside analogs inhibit mitochondrial 
DNA polymerase gamma at physiological doses led to a black box warning 
regarding mitochondrial toxicity with the use of these compounds.113 
A final potential mechanism of toxicity, which this project explores, is the 
inhibition of bile acid transport leading to the hepatocellular retention of bile acids 
(i.e., cholestasis). Perturbation of BSEP, the biliary efflux transporter, has been 
suggested to be a mechanism of DILI for a number of drugs reported to cause 
cholestasis such as troglitazone and bosentan.77,114 Evidence supporting 
interference with bile salt transporters as a mechanism of DILI continues to emerge.  
Consequently, a number of in vitro methods and models, including sandwich-
cultured hepatocytes, are now employed to screen for drug interactions with BSEP 
to predict and decrease the risk of DILI in humans.115,116 
 
PART III.  Bile Acid Synthesis, Hepatic Transport, and Molecular Regulation 
A.  Bile Acid Synthesis. 
  Bile acids, the main constituents of bile, are essential for the secretion of 
cholesterol from the liver.  Additionally, bile acids play a major role in the molecular 
regulation of enzymes and transporters involved  in the metabolism and distribution 
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of endogenous and exogenous compounds.117 Bile acids are formed by the 
conversion of cholesterol in the liver via two pathways: the classical (or neutral) 
pathway and the alternative (or acidic) pathway.  The classical pathway is common 
to all mammals, and accounts for ~75% of the total bile-acid pool.   Cholesterol 7 α-
hydroxylase (CYP7A1) is the first, rate-limiting enzyme in the classical pathway 
whereas the alternative pathway is initiated by sterol 27-hydroxylase (CYP27A1).118  
In the alternative pathway oxysterol intermediates are generated by 25-
hydroxycholesterol 7-alpha-hydroxylase (CYP7B1).  Sterol 12α-hydroxylase 
(CYP8B1) catalyzes the hydroxylation at position 12 of the steroid nucleus, forming 
the primary bile acid, cholic acid (CA) in both pathways.  All 7α-hydroxylated sterols 
undergo a series of enzymatic steps ultimately ending in their conversion to primary 
bile acids.119,120 A detailed depiction of bile acid synthesis is presented in Figure 1.3.   
CA and chenodeoxycholic (CDCA) acid are the main primary bile acids 
common to most species.  Primary bile acids are those formed in the liver via the 
synthetic pathways while secondary bile acids are formed by intestinal bacteria.  CA 
and CDCA are differentiated by the number and position of hydroxyl groups.121,122  
Cholic acid has 3 hydroxyl groups while chenodeoxycholic acid (identified in the 
domestic goose, hence the prefix “cheno”) has only 2 hydroxyl groups (thus, the 
term “deoxy”).  In humans, the most abundant pimary bile acids, in addition to CA 
and CDCA, are their respective secondary bile acids, deoxycholic acid (DCA) and 
lithocholic acid (LCA).   In rats, CDCA is also converted to muricholic acid.123  Most 
bile acids are conjugated predominantly to either glycine (in humans) or taurine (in 
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rats).117  A list of serum bile acids and their concentrations in rats is provided in 
Table 1.9.   
 
B.  Hepatic Transport of Bile Acids 
Following synthesis in the liver, bile acids are secreted into the bile and stored 
in the gallbladder.  Gallbladder contractions transfer the stored bile into the small 
intestine.   Once in the intestine, biliary bile acids move from the duodenum to the 
jejunum, and then into the ileum.117   The liver maintains bile acid homeostasis via 
negative feedback regulatory mechanisms.  Approximately 95% of bile acids are 
reabsorbed in the ileum, while the remaining bile acids undergo bacterial 
metabolism, forming secondary bile acids.  The portal circulation carries primary and 
secondary bile acids back to the liver where they are taken up primarily by active 
transport processes, completing the enterohepatic recycling process.  Enterohepatic 
recirculation (illustrated in Figure 1.4) enables efficient reusage of bile acids, and 
allows bile acids to act as regulators of their own synthesis and transport.121,122   
The hepatocyte contains both basolateral (sinusoidal) and apical (canalicular) 
membrane domains. Bile acids are transported to and concentrated in the bile via 
active transport systems.124  Bile acids move from the portal circulation into 
sinusoidal blood and through fenestrae, or pore-like openings, into the space of 
Disse. Basolateral uptake of bile acids into the hepatocyte is the initial step in the 
hepatic elimination of bile acids.  Once disassociated from albumin, bile acids readily 
transverse the basolateral membrane via transport proteins, as detailed below.125   
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The canalicular membrane forms the border of the bile canaliculus and serves 
as the primary excretory route of bile acids.  Biliary constituents are secreted into the 
bile against a steep concentration gradient; thus, canalicular excretion is the rate-
limiting step in biliary elimination.126  The following section highlights the localization 
and function of key bile acid transport proteins and discusses potential clinical 
implications of genetic defects. 
 
Basolateral Transport Proteins 
 
Sodium-taurocholate cotransporting polypeptide (NTCP) mediates the 
sodium-dependent uptake of conjugated bile acids from the portal blood.   NTCP 
electrogenically transports sodium ions and bile acid molecules simultaneously with 
a stoichiometry of 2:1.127  NTCP preferentially transports taurine- and glycine-
conjugated bile acids relative to the unconjugated species.  Also, NTCP displays a 
higher affinity for conjugates of dihydroxy bile acids (chenodeoxycholate and 
deoxycholate) than for conjugates of trihydroxy bile acids (cholate).128  To date, no 
known genetic mutation in NTCP has been associated with liver disease. However, 
numerous studies have demonstrated that NTCP mRNA and/or protein expression is 
downregulated in cholestatic conditions such as progressive familial intrahepatic 
cholestasis (PFIC), biliary atresia, chronic hepatitis C, and late stage primary biliary 
cirrhosis.129-132  Although genetic variants in NTCP have been identified, most 
variants display transport activity comparable to wildtype NTCP with the exception of 
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the c.668T>C variant, which exhibits minimal taurocholate and cholate transport and 
a greater affinity for rosuvastatin.133,134 
  
Organic Anion Transporting Proteins (OATPs) comprise a family of 
multispecific organic anion transporters that are responsible for the sodium-
independent uptake of bile acids as well as a broad range of organic anions and 
cations.  OATP1A2 transports a number of endogenous and exogenous substrates 
including conjugated and unconjugated bile acids, bilirubin, dehydroepiandrosterone 
sulfate (DHEAS), estrogen conjugates, and the antihistamine fexofenadine; 
OATP1A2 appears to contribute only minimally to total bile acid uptake.135  While 
there is overlap between OATP1B1 and -1A2 substrate specificity, OATP1B1 is 
reportedly the most important OATP transporter involved in sodium-independent bile 
acid uptake in humans.  Interestingly, Xiang et al. reported significantly higher 
fasting plasma bile acid concentrations in individuals with OATP1B1 polymorphisms, 
supporting the premise that OATP1B1 plays a key role in overall bile acid uptake.136  
OATP1B3 also transports conjugated bile acids; however, the involvement of 
OATP1B3 in total bile acid transport remains unclear.   
Rodent Oatp1a1 substrates are similar to OATP1A2, including conjugated 
and unconjugated bile acids.  Oatp1a1 is the most important sodium-independent 
bile acid uptake transporter in rats.135 Two additional transporters, Oatp1a4 and -
1b2, have been demonstrated to play a lesser role in bile acid uptake, relative to 
Oatp1a1, in rat.135  
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Multidrug Resistance-associated Proteins (MRPs) are ATP-dependent 
efflux transporters.  MRP3 and MRP4 are located on the basolateral membrane of 
hepatocytes.   MRP3 predominantly transports glucoronidated substrates such as 
mono- and bisglucuronosyl bilirubin.  Although rat Mrp3 has been shown to transport 
bile acids, including taurocholic acid and glycocholic acid with high affinity, human 
MRP3 only transports glycocholic acid with low affinity.137-139 Conversely, MRP4 
mediates the transport of monoanionic bile acids in a glutathione-dependent 
manner.140,141  Thus, MRP4 may contribute to the basolateral efflux of glutathione 
and bile acids from the hepatocyte into blood or across the apical membrane of renal 
proximal tubules.  
Under normal physiological conditions, translocation of bile acids across the 
basolateral membrane is predominantly influx, but under cholestatic conditions, 
basolateral efflux of bile acids via MRP3 and MRP4 is upregulated.142  MRP4 
reportedly transports sulfated bile acids and is significantly induced in the livers of 
farsenoid x receptor (FXR) null mice.90  Additionally, Denk et al. demonstrated up-
regulation of Mrp4 in the liver and down-regulation in the kidney of bile duct ligated 
rats.87 
 Although hepatic MRP3 expression in human livers under “normal” 
conditions is modest, induction of MRP3 has been reported in patients with primary 
biliary sclerosis and in individuals with Dubin-Johnson syndrome, a rare disorder 
characterized by prolonged conjugated hyperbilirubinemia.143  Additionally, 
increased sulfated bile acids in the serum under cholestatic conditions, such as 
progressive familial intrahepatic cholestasis-2 and -3, support the premise that 
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MRP3 and MRP4 are induced as a hepatoprotective mechanism to prevent the 
intracellular accumulation of potentially toxic bile acids.130   
   
Apical Transport Proteins 
 
Bile Salt Export Pump (BSEP) is the predominant canalicular transport 
protein responsible for the translocation of monovalent bile acids into the bile.124,126  
Modest levels of Bsep mRNA expression in the kidney, brain, and intestine of rats 
has been reported.  However, rodent Bsep is almost exclusively and homogenously 
expressed in the liver.144-146  In humans, high levels of BSEP mRNA were reported in 
both the testis and the liver.147  Low levels of Bsep also have been demonstrated in 
rat and human placenta during pregnancy.148 Studies in Sf9 and HEK293 cellular 
systems reveal that cholate as well as the taurine and glycine conjugates of cholate 
and chenodeoxycholate are transported by rat Bsep with high affinity (km values 
between 2 and 22 µM).  Similarly, human BSEP has been shown to transport 
taurocholate, glycocholate, and taurochenodeoxycholate.128 In humans, BSEP 
mutations have been associated with type 2 PFIC.149 Regulation of BSEP 
expression by bile acids via activation of FXR also has been reported.150  FXR-
mediated induction of BSEP is another hepatoprotective response to overcome 
cholestatic conditions.151  
Multidrug Resistance-associated Protein 2 (MRP2), first identified in the 
apical membrane of human and rat hepatocytes, facilitates the canalicular excretion 
of various exogenous and endogenous compounds including sulfate conjugates, 
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glutathione conjugates, and some unconjugated drugs like ampicillin and 
irinotecan.45,152  MRP2 also mediates the efflux of conjugated bilirubin and bile acids 
as a hepatic detoxification mechanism.124 Several genetic polymorphisms in MRP2  
also have been associated with Dubin-Johnson syndrome.153 Stimulation of ATP-
dependent vesicular bile acid transport by E217ßG has been shown in MRP2-
expressing Sf9 vesicles.154 
 
C.  Molecular Regulation of Bile Acid Homeostasis 
 Bile acid synthesis, metabolism, and transport processes are tightly regulated 
by a number of feedforward and feedback mechanisms at both the gene 
transcription level and posttranscriptionally. Bile acids are natural detergents, and 
can elicit mitochondrial toxicity by increasing membrane permeability, oxygen free 
radicals, and lipid peroxidation.155  Conversely, bile acids themselves act as 
signaling molecules in the regulation of enzymes and transport proteins involved in 
the metabolism and transport of bile acids, thereby preventing cellular accumulation 
and damage.124 
 Several nuclear hormone receptors and other transcriptional factors are key 
in the molecular regulation of bile acid formation and transport.  Bile acids are 
activating ligands for FXR which, in concert with its heterodimer partner retinoid X 
receptor (RXR), is a transcription factor for several bile acid transporters, including 
BSEP.124  Drugs like rifampin as well as endogenous compounds including 
lithocholate reportedly act as ligands for pregnane X receptor (PXR) in rodents and 
steroid X receptor (SXR) in humans to upregulate Oatp2 and Mrp2, respectively. 
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Upregulation of CYP7A1 by activation of the liver X receptor (LXR), culminating in 
increased bile acid synthesis, has been demonstrated by oxysterols.124  
 Wagner and colleagues demonstrated that agonists of the constitutive 
androstane receptor (CAR) and PXR stimulate alternate bile acid detoxification and 
elimination pathways in common bile duct-ligated mice.  Alterations in these 
pathways included induction of efflux transporters Mrp2-4 and upregulation of 
sulfotransferase (SULT) 2A1, a key enzyme in bile acid sulfation, as well as uridine 
diphosphate (UDP)-glucuronosyltransferase 1A1, the enzyme responsible for 
bilirubin glucuronidation.  These modifications resulted in decreased bile acids and 
bilirubin levels in plasma.156,157   
 Drugs and bile acids that alter hepatobiliary transporters have been employed 
as therapeutic drug targets.  Ursodeoxycholic acid (UDCA), for example, induces the 
expression and function of multiple transporters and enzymes at numerous levels 
including Mrp2, Bsep, and CYP3A4.  As such, evidence in the literature supporting 
the use of UDCA to promote adaptive reponses to combat cholestasis continues to 
emerge.158,159  
  The association between cholestasis, a common phenotype in a number of 
disease states, and altered expression and function of key bile acid enzymes and 
transporters remains unclear.  The coordinated regulation of hepatic bile acid 
formation, metabolism, and transporter-mediated elimination is an intricate, 
multifactorial adaptive system designed to preserve the integrity of the liver.  
However, as data illustrating the effects of molecular changes on bile acid 
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homeostasis are unveiled, therapeutic options for the management of cholestasis 
will continue to increase. 
 
Part IV.  In vitro Model Systems to Investigate the Hepatobiliary Transport of 
Drugs and Endogenous Compounds 
 The concept that key drug-transporter interactions can influence the overall 
disposition of compounds is gaining recognition in the field.  To date, in vitro models 
used to examine hepatic uptake and excretion are limited to transfected systems 
and cellular preparations from liver tissue.  Transfected systems are useful to 
evaluate interactions between drugs and specific transport proteins; however, it is 
difficult to determine the relative contribution of each protein to the overall disposition 
of a given substrate or inhibitor.  Additionally, the presence of endogenous 
transporters in transfected systems can make it difficult to accurately interpret 
experimental findings. 
Freshly isolated hepatocytes in suspension are often employed to evaluate 
drug-transporter interactions.  Limitations of this system, such as the rapid decline in 
cellular viability and an inability to distinguish between canalicular and basolateral 
efflux, confine the utility of this model to measuring short-term metabolism and 
characterizing initial hepatic uptake of substrates. Freshly plated hepatocytes in a 
gel entrapped design, i.e. sandwich-cultured hepatocytes, represent a diverse tool 
useful in evauating a number of physiological processes including hepatobiliary 
disposition of compounds, molecular regulation of transporters, and 
hepatotoxicity.160  Hepatocytes cultured in this configuration exhibit liver specific in 
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vivo properties such as cellular polarity, intact bile canalicular networks, and the 
formation and secretion of numerous endogenous substances including albumin, 
fibrinogen, urea, and bile acids.161  Additionally, studies demonstrating that calcium 
depletion disrupts tight junction networks of the bile canaliculi makes the model 
suitable for examining both the biliary excretion of compounds as well as the 
inhibitory potential of compounds on the biliary excretion of model substrates.162  
Sandwich-cultured hepatocytes are very useful to assess the CYP450 induction 
potential of compounds.  Studies performed using typical inducers demonstrate that 
sandwich-cultured hepatocytes retain induction responses similar to those observed 
in vivo.163   
In general, there are numerous powerful in vitro tools to investigate liver 
specific processes, each with advantages and disadvantages. The in vivo processes 
that govern drug disposition, efficacy, and toxicity are multifactorial.  Consequently, 
while there is currently no comprehensive in vitro model to accurately predict in vivo 
interplay between drugs, transporters and metabolic enzymes, the combined 
application of a variety of in vitro model systems provides valuable insight to 
identifying safe, effective drug candidates.   
 
Part V. Goals and Specific Aims 
 The global objective of this dissertation project was to develop a mechanistic 
understanding of how impaired bile acid transport proteins contribute to DILI.  
Particularly, the influence of combination antiretroviral PIs, LPV and RTV, on the 
hepatobiliary disposition of radiolabelled and endogenously formed bile acids was 
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investigated.  Recent literature demonstrated that individually, LPV and RTV are 
potent inhibitors of BSEP.  However, LPV is only available as a coformulation with 
RTV; their additive effect on BSEP remains unclear.  Thus, the combined effect of 
LPV and RTV on bile acid transport is a fundamental question that represents the 
cornerstone of the present work.  Several in vitro model systems, including freshly 
isolated suspended and sandwich-cultured hepatocytes were employed to conduct 
these investigations.  A secondary goal of this dissertation was to determine whether 
genetic variants in genes involved in bile acid transport or synthesis predispose 
patients to DILI.   
 
This dissertation addresses the following specific aims: 
SPECIFIC AIM 1: Elucidate the effects of LPV and RTV, alone and combined, on 
hepatocellular toxicity and hepatobiliary bile acid transport. 
Hypothesis: Coadministration of PIs increases the severity of inhibition of BA 
transport and, consequently, hepatocellular toxicity.  
Experimental Approach: 
• Following 24-hr exposure to LPV, RTV, and LPV/r, measure lactate 
dehydrogenase (LDH) and adenosine triphosphate (ATP) medium and 
cellular content as indicators of cellular apoptosis and viability. 
• Quantify the biliary excretion, biliary clearance, and cells + bile and cellular 
accumulation of model bile acids [3H]TCA and [14C]CDCA in sandwich-
cultured rat hepatocytes.  
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• Quantify the sodium-dependent and sodium-independent initial uptake rates 
of [3H]TCA and [14C]CDCA in freshly isolated suspended rat hepatocytes in 
the presence and absence of LPV, RTV, and LPV/r. 
SPECIFIC AIM 2: Investigate the influence of LPV and RTV, alone and combined, 
on the hepatocellular disposition of endogenous bile acids.  
Hypothesis: Combination LPV and RTV exerts additive effects on bile acid 
transporters, causing cellular retention and accumulation of bile acids.  
Experimental Approach: 
• Quantify and compare the effects of LPV, RTV, and LPV/r on the cellular 
accumulation and biliary excretion of endogenously synthesized primary bile 
acids in cells, bile, and medium of day 4 sandwich-cultured rat hepatocytes. 
SPECIFIC AIM 3: Determine whether genetic polymorphisms in key bile acid 
synthesis and transport genes are risk factors for DILI. 
Hypothesis: Functional genetic variants in genes that play a role in bile acid 
transport or synthesis increase the risk of DILI in humans.  Furthermore, variants in 
genes that act as compensatory mechanism(s) of BA excretion increase the risk of 
DILI.  
Experimental Approach: 
• Conduct a genetic association study using logistic regression analyses to 
determine whether the distribution of variants in bile acid metabolism and 
transport genes differ between patients from the Drug-induced Liver Injury 
Network (DILIN) and control subjects from the British Birth Cohort. 
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• Perform logistic regression analysis comparing distribution of genetic variants 
in DILIN patients who experienced toxicity due to BSEP inhibitors versus 
controls. 
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Figure 1.1 Schematic depicting the localization of SLC and ABC transport 
proteins involved in the translocation of protease inhibitors (PI) at sites of 
absorption (intestine), excretion (liver and kidney), and at target sites 
(central nervous system, lymphatic system, placenta, blood–testis barrier, 
and female genital tract). In general, PIs are transported (denoted by solid 
lines) into cells by proteins of the SLC family (e.g., OATPs and OCTs) and 
transported out of cells by proteins of the ABC family (e.g., P-gp, BCRP, 
and MRPs). The hepatic uptake and excretion of bile acids (BA), which are 
mediated by NTCP and BSEP, respectively, are inhibited (denoted by 
dashed lines) by PIs. The hepatic transport of bilirubin (bili), which is 
mediated by OATP1B1, is inhibited (denoted by dashed line) by PIs. PIs 
bind to pregnane X receptor (PXR), an orphan nuclear receptor, which 
forms a heterodimer with the retinoid X receptor (RXR) and mediates the 
induction of cytochrome P450 3A4 (CYP3A4). 
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Figure 1.2 Chemical Structures of Selected Protease Inhibitors 
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Figure 1.3 Classical (solid arrows) and Alternative (dashed arrows) Pathways of Bile 
Acid Synthesis. 
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Figure 1.4 Enterohepatic Circulation of Bile Acids 
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Table 1.1 Physicochemical properties and in vitro cellular accumulation ratios of HIV protease inhibitors 
 
aData obtained from Drugbank (http://www.drugbank.ca/drugs) 
bConflicting results reported 
cWhen coadministered with ritonavir (except nelfinavir); ritonavir: coadministered with saquinavir 
dFosamprenavir  
 Amprenavir 
(APV) 
[Fosamprenavir] 
Atazanavir 
(ATZ) 
Darunavir 
(DRV) 
Indinavir 
(IDV) 
Lopinavir 
(LPV) 
Nelfinavir 
(NLV) 
Ritonavir 
(RTV) 
Saquinavir 
(SQV) 
Tipranavir 
(TPV) 
pKa 1.9 a 
[6.28] 
4.3 14.2 6.2; 
5.9, 3.7 
1.6 6.0, 11.1  2.8  1.1, 7.1; 
7.0; 
5.5 b 
7.8 
Lipophilicity 
(Log P o/w) 
Log D (pH) 
1.7; 
3.3 or 4.2b 
[0.84] 
4.25; 
4.5 a 
1.8 a 0.9; 
2.9 a 
1.7 2.9;  
6 a 
4.0 (pH 7.4); 
4.1 (pH 6.0) 
1.2; 
5.2 
3.9 a 
1.9; 
4.1 
(mesylate); 
3.8  
6.9 a 
Solubility 
(µg/ml) 
Mesylate:  
Aq: 190 
pH 7.4: 60 
pH 6.8: 190 
[Calcium: Aq: 
700]d 
Aq: 4-5 
mg/mLa 
 
 
 
 
Ethanolate: 
Aq: 150 a 
Aq: 15 a 
Sulfate: 
Aq: > 100 
mg/ml 
pH 7.4: 70 
pH 4.8: 300 
pH 3.5: 60 
mg/ml 
Aq: very 
low 
Mesylate: 
Aq: 4500 
pH 7.4: very 
low 
pH 3.5: 500  
pH 2.6: 
4500 
Aq: 1 
pH 7.4: 
5.3 
pH 4: 
6.9 
Mesylate:  
Aq: 2220 
pH 7.4: 36 
pH 6.5: 73 
Aq: 
insoluble 
Intracellular 
Accumulation 
ratio’s (in 
vivo in 
blood)c 
3.2 1.2  0.29 1.55;  
0.7-2.1 
5.3 1.25;  
1.7;  
0.8-4.2  
3.64;  
4.9;  
1.5-6.7 
 
References 164-166 22,53,167  164-
166,168,169 
164,170 164-
166,170,171 
53,164-
166,170 
1,53,164-
166,170 
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Table 1.2 Summary of clinically relevant drug-drug interactions involving HIV protease inhibitors with evidence for a role 
of drug transporters in mediating the interactions: protease inhibitor as perpetrator drug. 
 
 
Transport 
Protein Victim Drug 
Protease 
Inhibitor Clinical Exposure Changes In Vitro Studies 
MDR1 
 
Tenofovir 
(TFV) 
disoproxil 
fumarate 
(TDF) 
ATV/r, 
DRV/r, 
LPV/r, 
SQV/r 
Plasma TFV AUC 1.1-1.4 × ↑ 
in combination with ATV/r, 
DRV/r, LPV/r, SQV/r.59,172 
• Efflux Ratio (ER) of TDF across 
MDCK-MDR1 is 34 (control); ER is 
significantly reduced to 4.3 (NFV), 
4.4 (LPV, RTV); 16 (ATV); 22 
(SQV); 24 (APV);59 
• Limited interaction of HIV PI with 
transporters involved in TFV 
disposition in the kidney (hOAT1/3, 
MRP4).173 
Fexofenadine 
120 mg 
LPV/r 
RTV 
AUC 2.2 × ↑ (single RTV 
100) 
AUC 4.0 × ↑ (single LPV/r 
400/100) 
AUC 2.9 × ↑ (steady-state 
LPV/r 400/100)174 
 
• RTV IC50 = 5.4 µM for P-gp-
mediated fexofenadine transport 
across Caco-2175 
• LPV and RTV are P-gp inhibitors 
and inducers 
• RTV causes net induction (rather 
than inhibition) of P-gp in vivo in 
rats – based on CsA oral BA 176 
 
Fexofenadine 
60 mg 
RTV 
200 tid - 400 bid 
AUC 2.8 × ↑ (acute RTV) 
AUC 1.4 × ↑ (steady-state 
RTV)177 
Fexofenadine 
60 mg IDV/r 800/100 bid 
AUC 5.0 × ↑ (single dose 
IDV/r) 
AUC 4.2 × ↑ (steady-state 
IDV/r) 54 
Largest change for IDV may be 
explained by P-gp being an inhibitor 
but not an inducer 
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Transport 
Protein Victim Drug 
Protease 
Inhibitor Clinical Exposure Changes In Vitro Studies 
MDR1 
 
Digoxin 0.4 
mg oral RTV200; 14d 
Plasma AUC 1.2 × ↑ 178 
 
• RTV blocks P-gp activity (Table 1.4) 
• RTV (>5µM) enhances digoxin 
(0.1µM) accumulation in RBE4 
cells179 
Digoxin 0.5 
mg iv RTV300 bid 
Plasma AUC 1.9 × ↑, Vd 1.8 
× ↑, Clrenal 1.5 × ↓, Clnon-renal 2 
× ↓180 
Digoxin 
0.4mg qd DRV600/r100 bid Plasma AUC 1.4 × ↑ 
181
 
• DRV and RTV block P-gp (Table 
1.4) 
Digoxin 0.5 
mg (oral) 
SQV1,000/r100 
bid Plasma AUC 1.5 × ↑
182
 
• SQV (>10µM) and RTV (>5µM) 
enhance digoxin (0.1 µM) 
accumulation in RBE4 cells179 
Digoxin 0.25 
mg (oral) TPV/r 
Plasma AUC 1.9 × ↑ after 
first dose 
Plasma AUC unchanged and 
Cmax 1.5 × ↓ at steady-
state70 See Tables1.4 and 1.6 
 
Digoxin 0.5 
mg (oral) 
LPV400/r100 bid 
(14 d) Plasma AUC 1.8 × ↑
55
 
Loperamide TPV750(/r200) 
 
Plasma AUC 2-3 × ↓: in vivo 
intestinal P-gp induction, also 
in presence of RTV as 
inhibitor 69 
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Transport 
Protein Victim Drug 
Protease 
Inhibitor Clinical Exposure Changes In Vitro Studies 
MDR1 
 
 RTV200 
Plasma AUC 2.2 × ↑: in vivo 
intestinal P-gp inhibition;69 no 
effect on brain PD 
(loperamide) 
See Table 1.4 
 
 RTV600 Plasma AUC 3.2 × ↑: in vivo intestinal P-gp inhibition56 
Delaveridine APV600 bid possibly partly due to intestinal P-gp induction72 See Table 1.6 
Tacrolimus 
Sirolimus APV/r 
Case report in HIV-infected 
patient indicates increased 
tacrolimus/sirolimus half-life 
and trough levels, attributed 
to CYP and/or P-gp inhibition 
by APV/r57 
See Table 1.4 
 
Tacrolimus DRV/r 
Case report: HIV-infected 
kidney-transplant patient 
required a tacrolimus dose 
equal to 3.5% of usual 
dose.58 
Sildenafil DRV/r 400/100 bid 
Plasma AUC 4 × ↑: possibly 
due to P-gp inhibition (or 
OATP inhibition).183 
Ketoconazole 
200 bid 
DRV/r 
400/100 bid 
Plasma AUC 3.1 × ↑: 
possibly due to P-gp 
inhibition (or OATP 
inhibition)184 
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Transport 
Protein Victim Drug 
Protease 
Inhibitor Clinical Exposure Changes In Vitro Studies 
MDR1 
Ketoconazole 
200 qd RTV 
Plasma AUC 3.4 × ↑: 
possibly due to P-gp 
inhibition (or OATP inhibition) 
185
 
See Table 1.4 
 
Ketoconazole 
200 single 
dose 
LPV/r 
400/100 bid 
Plasma AUC 3.0 × ↑: 
possibly due to P-gp 
inhibition (or OATP 
inhibition)186 
Ketoconazole 
200 qd 
FPV/r 
700/100 bid 
Plasma AUC 2.7 × ↑: 
possibly due to P-gp 
inhibition (or OATP inhibition) 
187
 
OATP/ 
BCRP Atorvastatin 
LPV/r 
TPV/r 
SQV/r (400/400 
bid) 
DRV/r (300/100 
bid) 
AUC 5.9 × ↑(LPV/r) 
AUC 9.4 × ↑(TPV/r)62 
AUC 3.4 ×↑(SQV/r) 188AUC 
4.0 × ↑ (DRV/r) 62,189 
• Atorvastatin is an OATP1B1 and 
BCRP substrate 190,191 
• HIV PI are OATP and BCRP 
inhibitors 41,192,193 
OATP1B1/ 
BCRP Rosuvastatin 
TPV/r 
LPV/r 
ATV/r 
AUC 1.4× ↑ (TPV/r)62 
AUC 2.1× ↑ (LPV/r); t1/2 not 
affected 172 
AUC 3.1× ↑ (APV/r) 194 
• Rosuvastatin is an OATP1B1 and 
BCRP substrate 190,191 
• LPV, TPV, ATV and RTV are OATP 
and BCRP inhibitors 41,192,193 
OATP1B1 
MRP2 
Pravastatin 
40 mg qd 
DRV/r 
600/100bid Plasma AUC 1.8 × ↑ 
181
 
See Table 1.4195 
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Transport 
Protein Victim Drug 
Protease 
Inhibitor Clinical Exposure Changes In Vitro Studies 
OATP/ 
MDR1 Fexofenadine 
NLF 1250 bid 
(1wk) 
Fexofenadine Cmax 1.3 × ↓, 
t1/2 1.3 × ↓; possibly due to 
intestinal P-gp and hepatic 
OATP induction71 
See Table 1.6 
OATP2B1 Elvucitabine 20 mg 
RTV 300 (single 
dose) 
Elvucitabine AUC 1.3 × ↓ and 
Cmax 1.7 ×  ↓; possibly due to 
inhibition of intestinal influx 
transporters 63 
See Table 1.4 for effect of RTV on 
OATP activity 
Uptake 
transporters Etravirine 
DRV/r 
(600/100 bid) 
100 bid: plasma AUC 1.6 ×  ↓ 
200 bid: plasma AUC 1.8 ×  
↑52,196 
Etravirine is not a substrate for P-gp, 
BCRP or MRP1-3.75 The role of uptake 
transporters has not been investigated. 
 Etravirine TPV/r (500/200 bid) Plasma AUC 4.2 ×  ↓ 
73
 
See Table 1.6 
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Table 1.3 Summary of clinically relevant drug-drug interactions involving HIV protease inhibitors with evidence for a role 
of drug transporters in mediating the interactions: protease nhibitor as victim drug. 
 
Transport 
Protein  
Perpetrator Drug 
(Inhibitor/Inducer) 
Victim 
Protease 
Inhibitor 
Clinical Exposure changes In Vitro Studies 
MDR1 
(ABCB1, 
P-gp) 
Rifampicin 
600 mg qd 
Most HIV PI Plasma AUC 5.6 × ↓ (APV) 
Plasma AUC significantly ↓ (ATV) 
Plasma AUC 9.1 ×  ↓ (IDV) 
Plasma AUC 5.6 ×  ↓ (NFV) 
Plasma AUC 2.9 ×  ↓ (RTV) 
Plasma AUC 6.3 × ↓ (SQV) 
 (possibly partly attributable to intestinal P-
gp induction)197  
HIV PI are (poor) P-gp 
substrates, but exact 
role of intestinal efflux 
transporters in their 
absorption unclear. 
31,39,198,199
 
 Rifampicin 
600 mg qd 
LPV/r 
800/200 mg qd 
400/400 mg qd 
Plasma AUC 4 × ↓ (LPV/r)76  LPV is an ABCB1 (but 
not ABCC2) substrate36 
 Rifampicin 
600 mg qd 
ATV/r  
300/100 mg qd 
Plasma AUC 6.7 × ↓ (ATV) and 2.9 × ↓ 
(RTV) (possibly partly attributable to 
intestinal P-gp induction; evaluated in three 
patients only) 200 
ATV and RTV are (poor) 
P-gp substrates.39 
MDR1 
(ABCB1, 
P-gp) 
Rifabutin  APV 
IDV 
NFV 
SQV 
Inductive effects on HIV PI PK is less 
pronounced (1.2-1.7×↓) than for 
rifampicin.197,201  
cfr. above  
MDR1 
(ABCB1, 
P-gp) 
SJW, Ginkgo and 
other herbal 
medicines 
Several HIV PI Reduced exposure, potentially leading to 
therapy failure (exact contribution of efflux 
transporters versus drug metabolizing 
enzymes not clear)202  
see Table 1.5 illustrating 
that HIV PI are 
substrates for efflux 
transporters 
 
 
45
 
 46 
 
Transport 
Protein 
Perpetrator Drug 
(Inhibitor/Inducer) 
Victim 
Protease 
Inhibitor 
Clinical Exposure changes In Vitro Studies 
MDR1 
(ABCB1, 
P-gp) 
Ketoconazole 
200 bid 
DRV/r 400/100 
bid 
 
Plasma DRV AUC 1.4 × ↑203 DRV is a P-gp substrate, 
even though RTV co-
administration limits the 
role of P-gp. 64,204 
MDR1 
(ABCB1, 
P-gp) 
Ketoconazole 
200-400 qd 
SQV/r 400/400 
bid 
Plasma SQV AUC 1.4 ×  ↑205 Ketoconazole inhibits P-
gp-mediated SQV 
transport across Caco-2 
monolayers.206   
MDR1 
(ABCB1, 
P-gp) 
Etravirine FPV700/r100 
bid 
IDV800 tid 
TPV500/r200 
bid 
ATV400 qd 
SQV1200 
single 
Plasma APV AUC 1.7 ×  ↑  
Plasma IDV AUC 1.5 ×  ↓ 
Plasma TPV AUC 1.2 ×  ↑ 
Plasma ATV AUC 1.2 ×  ↓ 
Plasma SQV AUC 1.5 ×  ↓73 
Etravirine has been 
shown to be a potent 
BCRP inhibitor and 
inducer in vitro, however 
PI are not BCRP 
substrates;40   etravirine 
shows no significant P-
gp inhibition, but modest 
induction of P-gp and 
MRP3 75 
OATP1B  
(SLCO1B)  
Rifabutin 
150 mg qod 
DRV/r 
600/100 mg 
bid 
DRV plasma AUC 1.6 ×  ↑ 
RTV plasma AUC 1.7 ×  ↑  
Mechanism unknown but possibility of SLC 
inhibition has been suggested.184  
No data available on 
effect of rifabutin on 
OATP activity 
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Table 1.4 HIV protease inhibitors as inhibitors of ABC and SLC transporters. 
 
 
 
ABC SLC 
Protease 
Inhibitor 
Transporter IC50* or 
Ki** (µM) 
System (Substrate) Ref Transporter  IC50* or Ki** 
(µM) 
System 
(Substrate) 
Ref 
Amprenavir P-gp 
 
BCRP 
23.1* 
 
181* 
BBMEC (rhodamine 123) 
 
MDCKII (Pheophorbide A) 
207 
 
41 
OATP1B1 
 
OATP1B3 
14.4*, 12.8** 
 
19.1*, 13.1** 
CHO (CGamF) 
 
CHO (CGamF) 
21 
 
21 
Atazanavir P-gp 
 
BCRP 
 
67.8* 
 
69.1* 
 
 
MDCKII (Calcein-AM) 
 
MDCKII (Pheophorbide A) 
 
 
37 
 
41 
 
OATP1B1 
 
OATP1B3 
 
OATP2B1 
1.7*, 1,5** 
 
3*, 3** 
 
2.2* 
 
3.6* 
CHO (CGamF) 
 
CHO (CGamF) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
21 
 
21 
 
22 
 
22 
Darunavir P-gp 33* 
 
>100* 
Not reported 
 
MDCKII (Calcein-AM) 
208 
 
37 
OATP1B1 
 
OATP1B3 
 
OATP2B1 
3.5*, 3.1** 
 
4.8*, 3.3** 
 
29* 
 
26* 
CHO (CGamF) 
 
CHO (CGamF) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
21 
 
21 
 
22 
 
22 
Indinavir P-gp 54.6* 
 
>100* 
BBMEC (rhodamine 123) 
 
MDCKII (Calcein-AM) 
207 
 
37 
OATP1B1 
 
 
 
OATP1B3 
 
OATP2B1 
 
OCT1 
 
12.2*, 10.8** 
 
5.84* 
 
12.3*, 8.5** 
 
3.9*, 3** 
 
37.6* 
 
62* 
CHO (CGamF) 
 
HeLa 
 
CHO (CGamF) 
 
Caco-2 (E3S) 
 
HEK293 (MPP) 
 
HeLa  
21 
 
209 
 
21 
 
21 
 
25 
 
26 
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ABC SLC 
Protease 
Inhibitor 
Transporter IC50* or 
Ki** (µM) 
System (Substrate) Ref Transporter  IC50* or Ki** 
(µM) 
System 
(Substrate) 
Ref 
Lopinavir P-gp 
 
BCRP 
10.3* 
 
7.66* 
MDCKII (calcein-AM) 
 
MDCKII (Pheophorbide A) 
37 
 
41 
OATP1B1 
 
OATP1B3 
 
OATP2B1 
0.5*,0.5** 
 
2*, 1.4** 
 
1.7* 
 
0.72* 
CHO (CGamF) 
 
CHO (CGamF) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
21 
 
21 
 
22 
 
22 
Nelfinavir P-gp 
 
 
 
BCRP 
1.7* 
 
19.9* 
 
13.5* 
 
 
12.5* 
BBMEC (rhodamine 123) 
 
MDCKII (calcein-AM) 
 
MDCKII  
(Pheophorbide A) 
 
HEK293 (mitoxantrone) 
207 
 
37 
 
41 
 
 
40 
OATP1B1 
 
OATP2B1 
 
OCT1 
 
 
 
OCT2 
0.93* 
 
2.2* 
 
0.9* 
 
22* 
 
7* 
 
13* 
HeLa (E217ßG) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
 
HeLa 
 
HEK293 (MPP) 
 
HEK293 (MPP) 
209 
 
22 
 
22 
 
26 
 
25 
 
25 
Ritonavir 
 
 
 
 
 
 
P-gp 
 
 
 
 
 
 
 
 
 
 
 
BCRP 
 
3.8* 
 
5* 
 
6.7* 
 
26.4* 
 
28.2* 
 
39.6* 
 
19.5* 
Caco-2 (digoxin) 
 
Caco-2 (digoxin) 
 
Caco-2 (rhodamine 123) 
 
BBMEC (rhodamine 123) 
 
MDCKII (digoxin) 
 
MDCKII (calcein-AM) 
 
HEK293 (mitoxantrone) 
106 
 
210 
 
211 
 
207 
 
212 
 
37 
 
40 
OATP1B1 
 
 
 
 
 
OATP1B3 
 
OATP2B1 
 
 
 
 
0.71* 
 
0.78** 
 
1.6*, 1.4** 
 
3.6*, 2.5** 
 
6.3*, 4.8** 
 
0.93* 
 
2.2* 
 
HeLa (E217ßG) 
 
HEK293 (pitavastatin)  
 
CHO (CGamF) 
 
CHO (CGamF) 
 
Caco-2 (E3S) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
 
209 
 
213 
 
21 
 
21 
 
21 
 
22 
 
22 
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ABC SLC 
Protease 
Inhibitor 
Transporter IC50* or 
Ki** (µM) 
System (Substrate) Ref Transporter  IC50* or Ki** 
(µM) 
System 
(Substrate) 
Ref 
  
   
OATP1A2 
 
 
 
OCT1 
<10* 
 
5.2* 
 
14* 
HeLa (fexaofenadine) 
 
HeLa 
 
HEK (MPP) 
214 
 
26 
 
25 
  
   
 
 
OCT2 
 
MATE1 
25* 
 
13.9* 
 
15.4* 
HEK (MPP) 
 
HeLa 
 
HeLa (metformin) 
25 
 
215 
 
215 
Saquinavir P-gp 
 
BCRP 
1.4* 
 
27.4* 
 
19.5* 
BBMEC (rhodamine 123) 
 
MDCKII (Pheophorbide A) 
 
HEK293 (mitoxantrone) 
207 
 
41 
 
40 
OATP1B1 
 
 
 
 
 
OATP1B3 
 
OATP1A2 
 
OATP2B1 
 
 
 
 
OCT1 
 
1.23* 
 
2.1*, 1.8** 
 
1.59** 
 
4.1*, 2.8** 
 
<10 
 
5.3*, 4** 
 
3.5* 
 
4.6* 
 
8.3* 
 
37* 
HeLa (E217ßG) 
 
CHO (CGamF) 
 
HEK293 (pitavastatin) 
 
CHO (CGamF) 
 
HeLa (Fexofenadine) 
 
Caco-2 (E3S) 
 
Caco-2 (E3S) 
 
MDCKII (E3S) 
 
HeLa 216 
 
HEK293 (MPP) 
209 
 
21 
 
213 
 
21 
 
214 
 
21 
 
22 
 
22 
 
26 
 
25 
Tipranavir  
   
OATP2B1 0.77* 
 
0.88* 
Caco-2 (E3S) 
 
MDCKII (E3S) 
22 
 
22 
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Table 1.5 HIV protease inhibitors as substrates of ABC and SLC transporters 
 
 
 
 
 
 
 
 
 
 ABC SLC 
Protease 
Inhibitor 
Transporter Km* (µM) or 
ER (PI dose)** 
In vitro 
System 
Ref Transporter Km* (µM) or 
ER (PI dose)** 
In vitro 
System 
Ref 
Amprenavir P-gp 47* 
 
24.2 (10 µM)** 
High Five 
membranes 
MDCKII-MDR1 
207 
 
217 
    
Indinavir P-gp 0.47* 
 
2.1* 
High Five 
membranes 
High Five 
membranes 
218 
 
207 
    
Nelfinavir P-gp 3.6* High Five 
membranes 
 
207     
Ritonavir P-gp 0.8* LLC-PK1 219     
Saquinavir P-gp 1.4* 
 
14.5* 
 
15.4* 
High Five 
membranes 
LLC-PK1 
 
Caco-2 
207 
 
219 
 
220 
OATP1A2 36.4* Oocytes 18 
Tipranavir P-gp 5.9 (8.1 µM)** Caco-2 69     
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Table 1.6 In vitro induction data with HIV protease inhibitors 
Transporter HIV PI Model System (marker): Effect (conc)  Reference 
MDR1 APV T84 (0.1µM digoxin ER): ER doubled (10µM; 72h) 
T84 (mRNA): 5× ↑ (10µM; 72h) 
LS180 (mRNA): 17× ↑ (10µM; 96h) 
96,221 
 ATV LS180V (protein): 2.5× ↑ (30 µM, 3 d) 
LS180V (Rh123 uptake): 55%↓ (30 µM, 3 d)  
hCMEC/D3 cells (protein): 2.5× ↑ (10 µM; 3d)  
LS180 (mRNA): 5× ↑ (10µM; 96h) 
96,222,223 
 DRV LS180 (mRNA): 3.8× ↑ (10µM; 1wk) 34 
 IDV No significant P-gp induction 96,222,223 
 LPV LS-180V (protein/mRNA): 3× ↑ (30 µM 72h) 
LS-180V (Rh123 uptake): 50%↓ (30 µM 72h) 
LS180 (mRNA): 12× ↑ (10µM; 96h) 
96,222-224 
 NFV Cultured Hepatocytes (mRNA): 4-6× ↑ (10-25 µM) 
Cytotrophoblast culture (Rh123 uptake): 23% ↓ (3 
µg/ml; 24h) 
LS180 (mRNA): EC50 = 1.2 µM (96h); LS180 
(mRNA): 7× ↑ (10µM; 96h) 
67,96,225 
 
 
 
 
 
 
RTV Human hepatocytes (mRNA): 9-10× ↑ (10-25 µM)  
LS-180V cells (protein): 6× ↑ (1-100 µM; 3d) 
LS-180V (Rh123 uptake): 50%↓ (>10 µM; 3d) 
hCMEC/D3 cells (protein): 2× ↑ (10 µM; 3d)  
LS180 (mRNA): EC50 = 1.7 µM (96h); LS180 
(mRNA): 12× ↑ (10µM; 96h) 
67,96,97,223,226 
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Transporter HIV PI Model System (marker): Effect (conc)  Reference 
 SQV LS180 (mRNA): 5.7× ↑ (10µM; 1wk) 
Cytotrophoblast culture (protein): 2× ↑ (1 µg/ml; 24h) 
Cytotrophoblast culture (Rh123 uptake): 18% ↓ (1 
µg/ml; 24h) 
LS180 (mRNA): 5× ↑ (10µM; 96h) 
34,96,225 
 TPV LS180 (mRNA): 10× ↑ (10µM; 96h) 96 
MRP1 RTV LS-180V cells (protein): 3× ↑ (1-100 µM; 3d) 
LS-180V (CBF uptake): 30% ↓ (30 µM; 3d) 
97 
 SQV LS180 (mRNA): 2.3× ↑ (10µM; 1wk) 34 
MRP2 NFV Human hepatocytes (mRNA): 2-4× ↑ (10-25 µM) 67 
 RTV Human hepatocytes (mRNA): 5-6× ↑ (10-25 µM) 67 
 SQV LS180 (mRNA): 4.5× ↑ (10µM; 1wk) 34 
MRP3 SQV LS180 (mRNA): 2× ↑ (10µM; 1wk) 34 
MRP4 SQV LS180 (mRNA): 1.8× ↑ (10µM; 1wk) 34 
MRP5 SQV LS180 (mRNA): 3.8× ↑ (10µM; 1wk) 34 
BCRP NFV Human hepatocytes (mRNA): < 2× ↑ (10-25 µM) 67 
 RTV Human hepatocytes (mRNA): 2-3× ↑ (10-25 µM) 67 
 SQV LS180 (mRNA): 4.1× ↑ (10µM; 1wk) 34 
OATP1B1 NFV Hepatocytes (mRNA): 2-3× ↑ (10-25 µM) 67 
 RTV Hepatocytes (mRNA): 2× ↑ (10-25 µM) 67 
 SQV LS180 (mRNA): 4.6× ↑ (10µM; 1wk) 34 
OATP1B3 NFV Human hepatocytes (mRNA): 2-5× ↑ (10-25 µM) 67 
 RTV Human hepatocytes (mRNA): 3-4× ↑ (10-25 µM) 67 
OATP2B1 DRV LS180 (mRNA): 1.9× ↑ (10µM; 1wk) 34 
 SQV LS180 (mRNA): 1.8× ↑ (10µM; 1wk) 34 
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Table 1.7 Clinically Relevant Examples of Transporter-mediated Interactions between HIV Protease Inhibitors and 
Endogenous Compounds.  
 
Endogenous 
Compound  
Transport Protein Protease Inhibitor In Vitro Studies Clinical Relevance 
Bile salts NTCP 
BSEP 
RTV, SQV Inhibition of bile acid 
transport 78 
Increased serum bile 
acids; 
Increased hepatocyte 
bile acids; Increased 
risk for hepatotoxicity 
Palmitate CD36 and CPT1 fatty 
acid transporters 
LPV/r and DRV/r (not 
ATV/r) 
Inhibition of palmitate 
uptake in cultured 
skeletal muscle cells 
(myotubes)82  
Dyslipidaemia, insulin 
resistance 
Bilirubin OATP1B1 ATV, IDV Potent inhibition of 
OATP1B activity by 
HIV protease inhibitors 
causing increased 
incidence of 
hyperbilirubinemia and 
jaundice47,81 
Increased serum 
bilirubin levels 
associated with the 
use of specific 
protease inhibitors.80  
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Table1.8 Key Pharmacokinetic Parameters of the HIV Protease Inhibitors. 
 
 
 
 
 
 
Compound Standard 
Dosing 
Level 
Metabolism 
and Elimination 
t1/2ß (h) Plasma 
Protein 
Binding 
(%) 
Ritonavir 
Boosting 
effect 
Oral 
Bioavailability 
(%); 
[unboosted] 
DME 
interactions 
(based on 
boosted use 
in the clinic) 
Refs 
Amprenavir 
(from 
fosamprenavir) 
700 mg 
b.i.d. /r 
100 mg  
b.i.d. 
hepatic 3A4, 
2D6 urine:14%; 
feces:75 % ; 
(unchanged:1% 
urine; ND in 
feces) 
7-12 90 Cmax 1.5 
× ⬆ 
AUC > 2 
× ⬆ 
Ctrough 4 × 
⬆ 
30-70 CYP3A 187,227 
Atazanavir 300 mg 
q.d. /r 100 
mg  q.d. 
hepatic 3A4; 
Non-linear (300-
600 mg), 79% 
bile/13% urine; 
UD % dose in 
bile 20%, in 
urine 7% 
6 (in HIV 
patients; 2 
× ↓ in 
healthy 
volunteers) 
86 Ctrough 5 × 
⬆ 
AUC 3 × 
⬆ 
68; pH 
dependent, 
AUC 1.7 × ⬆ 
with food 
CYP3A, 
UGT1A1 
227,228 
Darunavir 600-800 
mg b.i.d. /r 
100 mg 
b.i.d. 
Hepatic 
CYP3A4 Feces: 
79.5%; urine:  
13.9% 
Unchanged 
(unchanged: 
41.2% in feces;   
7.7 % in urine) 
 
15 95 
 
AUC 10 × 
⬆  
82 [37] Inh.: 
CYP3A4, 
CYP2D6 
Ind.: 
CYP2C9 
CYP2C19 
 
181,227,229 
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Compound Standard 
Dosing 
Level 
Metabolism and 
Elimination 
t1/2ß (h) Plasma 
Protein 
Binding 
(%) 
Ritonavir 
Boosting 
effect 
Oral 
Bioavailability 
(%); 
[unboosted] 
DME 
interactions 
(based on 
boosted use 
in the clinic) 
Refs 
Indinavir 800 mg 
b.i.d. /r 
100 mg  
b.i.d. 
hepatic CYP3A4;  
19% and 83% 
recovered in 
urine and feces, 
respectively; Of 
this unchanged 
drugs accounted 
for 19.1% and 
9.4%  and in the 
urine and feces, 
respectively 
2 61 AUC 2 × ⬆  
Cmin > 4 × 
⬆  
60-65 CYP3A4 
Weak 2D6 
inhibitor 
227,230 
Lopinavir 400 mg 
b.i.d. /r 
100 mg 
b.i.d. 
hepatic CYP3A4 
10.4 % and 82% 
in urine and 
feces, 
respectively. Of 
this, 2.2 and 
19.8% appeared 
unchanged in the 
urine and feces 
respectively 
5-6 99 AUC 1.5 × 
⬆ 
 
Cmin 2 × ⬆ 
CSS 15-20 
× ⬆ 
 
 
 
Not 
established 
(increased 
AUC and 
Cmax under 
fed conditions 
however) 
CYP3A4 186,227 
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Compound Standard 
Dosing 
Level 
Metabolism and 
Elimination 
t1/2ß (h) Plasma 
Protein 
Binding 
(%) 
Ritonavir 
Boosting 
effect 
Oral 
Bioavailability 
(%); 
[unboosted] 
DME 
interactions 
(based on 
boosted use 
in the clinic) 
Refs 
Nelfinavir 635 mg 
b.i.d. 
hepatic CYP3A4, 
2C19, 2D6, 2C9 
2% and 87% 
recovered in 
urine and feces, 
respectively.  Of 
this, 22% and 1 
% was 
unchanged in the 
urine and feces, 
respectively 
1.8-3.4 99 AUC 2.5 × ⬆  
Cmax 1.4 × ⬆ 
 
> 78 CYP3A 
CYP2C19 
227 
Ritonavir PI + 100 
mg b.i.d. 
hepatic CYP3A4 3-5 99  66-75  227 
Saquinavir 1 g b.i.d. 
/r 100 mg 
b.i.d. 
hepatic CYP3A4 13 98  < 20 (Soft 
Gelatin 
Capsule) 
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Table 1.9 Serum bile acid concentrations in the rat 
   
  Concentration (µM) 
Bile Acid Species Wang et al.231 Bai et al.232 
GCA 0.1 + 0 0.12 + 0.07 
GCDCA 0.2 + 0.1 0.04 + 0.0 
GDCA 0.3 + 0.2 0.12 + 0.07 
CA 3.2 + 0.8 1.81 + 1.34 
UDCA 0.6+ 0.2 0.04 + 0 
GLCA 0.04 + 0 0.04 + 0.0 
CDCA 0.8 + 0.4 0.16 + 0.16 
DCA 0.6 + 0.1 0.04 + 0.0 
TCA 0.3 + 0.1 1.09 + 0.15 
TUDCA 0.1 + 0 0.04 + 0 
TCDCA 0.2 + 0.1 0.04 + 0 
TDCA 0.2 + 0.1 0.04 + 0 
Total Bile Acids 7.3 + 1.4 3.28 + 1.66 
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CHAPTER 2 
 
COMBINATION ANTIRETROVIRAL PROTEASTE INHIBITORS ALTER 
EXOGENOUS AND ENDOGENOUS BILE ACID DISPOSITION IN SANDWICH-
CULTURED RAT HEPATOCYTES  
 
Antiretroviral protease inhibitors (PIs) continue to be a mainstay in the treatment of 
HIV infection.  Despite their success, PIs have been associated with drug-induced 
liver injury (DILI) which is one of the most common adverse events leading to the 
discontinuation of PI-inclusive antiretroviral therapy.233,234  Liver injury occurred in 
1% to 9.5% of PI-treated patients in randomized clinical trials conducted prior to US 
Food and Drug Administration approval.235  Retrospective and prospective cohort 
studies report an overall incidence rate of hepatotoxicity associated with PI-inclusive 
drug therapy between 5% and 23%.   However, the PI dose and the definition of 
hepatotoxicity varied across studies.110  In particular, ritonavir (RTV)-containing 
regimens reportedly increased the risk of hepatotoxicity by 8.6-fold.234  RTV is now 
administered at subtherapeutic (and subtoxic) doses to enhance systemic 
concentrations of coadministered PIs.  One commonly prescribed PI combination is 
lopinavir and ritonavir (LPV/r).2  Reportedly, patients on highly active antiretroviral 
therapy (HAART) containing LPV/r who experienced liver failure had higher LPV/r 
plasma concentrations compared to patients with normal functioning livers.186 One 
proposed mechanism for DILI is that drugs and/or their metabolites impair the 
function of transport proteins responsible for the efflux of bile acids from 
                                                 
This chapter has been submitted for publication in Toxicological Sciences and is presented in the 
style of that journal. 
 59 
 
the hepatocyte.115,116,236 Bile acids can cause cellular necrosis and apoptosis as a 
result of mitochondrial damage and disruption of cell membranes due to the 
detergent-like effects of these molecules.237   Interference with the efflux of bile acids 
from hepatocytes could cause intracellular accumulation of bile acids, leading to 
toxicity. 
The major transport protein responsible for biliary excretion of bile acids from 
the hepatocyte is the bile salt export pump (BSEP).  Recent studies have shown that 
many drugs implicated in DILI inhibit BSEP.238  PIs including LPV and RTV also 
have been shown to inhibit bile acid transport via BSEP,78,239 supporting the idea 
that intracellular accumulation of bile acids may be a mechanism for DILI observed 
in patients treated with this combination.238,239  If this is correct, we reasoned that the 
combination of LPV and RTV used in the clinic may have an additive or even 
synergistic effect on BSEP inhibition, resulting in an increased risk of DILI.   
To our knowledge, the effect of PI combinations on hepatocyte viability and 
bile acid uptake and/or efflux, has not been studied previously.  Therefore, we 
examined the effects of LPV, alone and combined with RTV, on hepatocyte viability, 
bile acid transport, and endogenous bile acid disposition in rat hepatocytes.   We 
hypothesized that each PI would cause hepatocellular accumulation of bile acids 
and toxicity, and that co-administration of RTV and LPV would have at least an 
additive effect on bile acid accumulation and toxicity.    
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MATERIALS AND METHODS 
Chemicals. [3H]Taurocholic acid (TCA, 5 Ci/mmol; purity > 97%) was 
purchased from Perkin Elmer (Waltham, MA). [14C]Chenodeoxycholic acid  (CDCA; 
50 mCi/mmol; purity > 97%) and [14C]inulin (2.8 mCi/g, purity > 97%) were 
purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO).  RTV was 
obtained initially from the National Institutes of Health AIDS Research and 
Reference Reagent Program, Division of AIDS, National Institute of Allergy and 
Infectious Diseases, National Institutes of Health. In addition, RTV, LPV and d4 TCA 
were purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).  The 
d8 TCA was purchased from Martrex, Inc. (Minnetonka, MN).  All other deuterated 
bile acids were purchased from CDN Isotopes, Inc. (Pointe-Claire, Quebec, 
Canada).  The bile acids α- and ß-tauromuricholic acid (α/ß-TMCA) were purchased 
from Steraloids, Inc. (Newport, RI).  TCA, lactate dehydrogenase (LDH), adenosine 
triphosphate (ATP), Triton X-100, Hanks’ balanced salt solution (HBSS) premix, 
HBSS modified (with no calcium chloride, magnesium sulfate, phenol red and 
sodium bicarbonate) premix, dexamethasone, and collagenase (type IV) were 
purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO) was 
obtained from Fisher Scientific (Fairlawn, NJ).  GIBCO brand fetal bovine serum, 
recombinant human insulin, and Dulbecco’s modified Eagle’s medium (DMEM) were 
purchased from Invitrogen (Carlsbad, CA). Insulin, transferrin, and selenium (ITS) 
Universal Culture Supplement Premix and Matrigel™ Basement Membrane Matrix 
were obtained from BD Biosciences (Palo Alto, CA). The CellTiter-Glo® Luminescent 
Cell Viability Assay was purchased from Promega (Madison, WI).  LDH Cytotoxicity 
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Detection Kit was purchased from Roche Applied Sciences (Indianapolis, IN). All 
other chemicals and reagents were of analytical grade and were readily available 
from commercial sources. 
Hepatocyte Isolation and Culture in a Sandwich Configuration. 
Hepatocytes were isolated from male Wistar rats (270–300 g) obtained from Charles 
River Laboratories, Inc. (Raleigh, NC) using a two-step collagenase perfusion 
method previously described.163  Animals had free access to water and food before 
surgery and were allowed to acclimate for at least five days. All animal procedures 
complied with the guidelines of the Institutional Animal Care and Use Committee 
(University of North Carolina, Chapel Hill, NC). 
Hepatocytes were seeded at 1.75 x 106 cells/well on 6-well, or 0.35 x 106 
cells/well on 24-well, BioCoatTM collagen plates in DMEM containing 5% fetal bovine 
serum, 10 µM insulin, 1 µM dexamethasone, 2 mM L-glutamine, 1% MEM non-
essential amino acids, 100 units penicillin G sodium and 100 µg streptomycin 
sulfate.  Cells were incubated for 2 h at 37ºC in a humidified incubator (95% O2, 5% 
CO2) and allowed to attach to the collagen substratum, after which time the medium 
was aspirated to remove unattached cells, and replaced with fresh medium.  
Approximately 24 hours later cells were overlaid with BD MatrigelTM at a 
concentration of 0.25 mg/ml in ice-cold feeding medium (DMEM with 1% ITS, 0.1 µM 
dexamethasone, 2 mM L-glutamine, 1% MEM non-essential amino acids, 100 units 
penicillin G sodium and 100 µg/ml streptomycin sulfate). The culture medium was 
changed daily thereafter.  Rat hepatocytes were cultured for at least 3 days to allow 
for the formation of bile canalicular networks.  
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Cytotoxicity and Cell Viability Assays. Following 24-hour exposure to PIs, 
intracellular ATP levels were measured using the CellTiter-Glo® Luminescent Cell 
Viability Assay.  All reagents were allowed to equilibrate to room temperature prior to 
use. The CellTiter-Glo® Reagent was prepared by adding lyophilized CellTiter-Glo® 
substrate to CellTiter-Glo® buffer and mixing by vortex. Hepatocytes cultured in 24-
well plates were allowed to equilibrate for at least 30 min to reach room temperature 
before the assay was performed. Medium was aspirated from each well twice, and 
replaced with equal volumes of fresh feeding medium and CellTiter-Glo® reagent.  
Plates were placed on an orbital shaker for 2 min to induce cell lysis, and then 
incubated at room temperature for 10 min to allow the luminescent signal to 
stabilize. 
LDH leakage into sandwich-cultured rat hepatocyte (SCRH) medium was 
determined using the LDH Cytotoxicity Detection Kit.  Briefly, day 3 SCRH in 24-well 
plates were exposed to PIs for 24 hours, after which cell-free supernatant was 
collected and aliquots were placed in individual wells of a 96-well plate. The 
substrate mixture was added to the culture supernatant and incubated for 30 min.  
During this time, LDH released from hepatocytes into the supernatant reduced the 
tetrazolium salt 2-(4-iodophenyl)-3-(4- nitrophenyl)-5-phenyl-2H-tetrazolium chloride 
(INT) to formazan by a coupled enzymatic reaction. Following incubation, formazen 
formation was measured directly in the 96-well opaque-walled microplate by an 
ELISA absorbance plate reader. To directly compare assays, LDH data were 
converted to viability, and expressed as a percentage of control by subtracting the 
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degree of toxicity (%) from 100%.  Maximum cell death was represented by the 
values measured following complete cell lysis by 0.5% Triton X-100. 
Bile Acid ([3H]TCA and [14C]CDCA) Accumulation Studies in Sandwich-
Cultured Rat Hepatocytes. The model bile acid, TCA, and the unconjugated 
organic acid, CDCA, were used for transport studies. Day 4 SCRH seeded in 24-well 
plates were washed 3 times (20 sec per wash) and co-incubated for 10 min with 
Ca2+-containing (standard; cells + bile) or Ca2+-free (cells) HBSS buffer to maintain 
or disrupt tight junctions, respectively. Next hepatocytes were co-incubated for 10 
min with TCA (1 µM cold TCA plus trace [3H]TCA) or [14C]CDCA (1 µM cold CDCA 
plus 4 µM [14C]CDCA) in the presence or absence of individual or combined PIs in 
standard HBSS at 37ºC. Cells were then aspirated twice and uptake was terminated 
by rinsing wells with 2.0 ml of ice-cold standard HBSS. Following rinsing, cells were 
lysed with 0.1% Triton X-100 in phosphate-buffered saline, and placed on an orbital 
shaker for 20 min.  Aliquots of sample (500 µL) and dosing solution (100 µL) were 
collected for quantification of radioactivity by liquid scintillation counting. Another 500 
µl aliquot of sample was reserved for protein quantification using the Pierce BCA™ 
Protein Assay Kit (Thermo Scientific, Rockford, IL). To correct for nonspecific 
binding to the collagen substratum, [3H]TCA and [14C]CDCA accumulation in 
BioCoat™ plates without cells was subtracted from raw values. 
[3H]TCA and [14C]CDCA Initial Uptake in Suspended Rat Hepatocytes. 
The initial uptake of TCA (1 µM cold TCA plus trace [3H]TCA; 60 nCi/ml) and CDCA 
(0.5 µM cold CDCA plus 0.5 µM [14C]CDCA; 25 nCi/ml) in suspended rat 
hepatocytes was measured in the presence of vehicle (DMSO), LPV (10 µM) or RTV 
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(5 µM), alone and combined, using methods previously described.240 Uptake studies 
were performed in Na+-containing buffer to measure total uptake (Na+-dependent 
and Na+-independent), and Na+-free, choline-containing buffer (Na+-independent 
uptake only). Na+-dependent uptake was calculated by subtracting the Na+-
independent uptake from the total uptake). Briefly, cells were washed 2 times in ice-
cold buffer containing sodium chloride or choline chloride (137 mM NaCl or choline 
chloride, 0.8 mM MgSO4, 10 mM HEPES, 1.2 mM CaSO4, 0.86 mM K2HPO4, 0.14 
mM KH2PO4, and 5 mM glucose, pH 7.4). Cells were resuspended at 1.0 x 106 
cells/ml in the same buffer, kept on ice, and used immediately in experiments. 
Hepatocyte suspensions (4 ml; n = 3 livers, in triplicate) were preincubated in bottom 
inverted Erlenmeyer flasks at 37°C for 5 min; 0.1% DMS O or PIs were added 30 sec 
before, followed by [3H]TCA (1 µM unlabeled TCA plus trace [3H]TCA, 60 nCi/ml). At 
15, 30, and 45 sec, 200 µL samples of the cell suspension were collected and 
placed in a 0.4 ml polyethylene tube containing a top layer of silicone oil:mineral oil 
(82:18 [v/v], 100 µL) and a bottom layer of 3M KOH (50 µL), and immediately 
centrifuged. Radioactivity in the cell pellet and in the supernatant was measured by 
liquid scintillation counting. Adherent fluid volume was determined by incubating 
cells with [14C] inulin (60 nCi/ml) as reported by Baur et al.241  Uptake was 
normalized to protein concentrations for individual hepatocyte suspensions as 
determined by the BCA protein assay reagent kit. Cellular viability of the suspended 
hepatocytes (> 90%) was determined by trypan blue exclusion at the beginning and 
end of each experiment.    
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Accumulation of Endogenous Bile Acids in Cells + Bile, Cells, and 
Culture Medium of Sandwich-Cultured Rat Hepatocytes. Following 24 hour 
exposure to vehicle or PIs, 1 mL aliquots of medium were collected from day 4 
SCRH in 6-well format and stored at -80˚ C until analysis. The remaining culture 
medium was aspirated from all wells, and triplicate wells were rinsed with 1.5 ml/well 
of warmed HBSS containing calcium (cells + bile) or HBSS without calcium (cells 
alone).  Following rinses, wells were aspirated twice and another 1.5 ml of HBSS 
with or without calcium was added to the wells and cells were incubated at 37˚C for 
4 min. After incubation, the HBSS buffer was aspirated from all wells. Plates were 
sealed and stored at -80˚ C until analysis. 
LC-MS/MS Analysis. Culture medium and cell lysate samples were prepared 
for LC-MS/MS analysis as described previously 242.  Briefly, six endogenous 
conjugated bile acid species [taurocholic acid (TCA), glycoholic acid (GCA), 
taurochenodeoxycholic acid (TCDCA), glycochenodeoxycholic acid (GCDCA), and 
α/ß-tauromuricholic acid (α/ß TMCA)] were detected simultaneously; 10 µL of 
sample or calibration standards were injected onto a Shimadzu binary high-
performance liquid chromatography system (Columbia, MD).   Chromatographic 
conditions used were as follows: 60% 0.5 mM ammonium acetate:40% MeOH 
(solvent A) and 20% 0.5 mM ammonium acetate:80% MeOH (solvent B) at a flow 
rate of 50 µL/min.  The initial mobile phase was 70% solvent A:30% solvent B.  The 
gradient was increased rapidly to 100% of solvent B for 2-15 min, and then returned 
to initial conditions (solvent A) for 1 min.  The autosampler was maintained at 4°C 
and rinsed with 1500 µl of 50:50 (v/v) 50% methanol:50% water following aspiration. 
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Methanol (100%) was added at 10 µl/min as a post-column solvent. Tandem mass 
spectrometry used to quantify analytes was performed using a Thermo Electron 
TSQ Quantum Discovery MAX (Thermo Fisher Scientific) with an Ion Max ESI 
source in negative ion electrospray ionization mode using selected reaction 
monitoring. The concentration ranges of the standard curves for rat cell lysate and 
medium of each bile acid were 0.5-100 pmol/well and 0.5-50 pmol/100 µl of medium, 
respectively. For a detailed list of the transitions monitored at unit resolution, see 
Marion et al., 2011. 
When rat lysate and medium samples were analyzed initially, LC-MS/MS raw 
data were collected on α- and β-TMCA, but not processed. Both α- and β-TMCA 
have the same MS precursor and product negative ions as TCA, thus, their MS data 
were collected in the same analytical run as TCA. Once standards for α- and β-
TMCA became available, they were utilized to confirm the identity of the LC-MS/MS 
response in the TCA channel thought to be α/β-TMCA. Because of the 
chromatographic separation utilized here, TCA was well resolved from α- and β-
TMCA; however, α- and β-TMCA, which are stereoisomers, were measured 
collectively (designated α/β-TMCA). Utilizing recently generated standard curves for 
β-TMCA from rat lysate (10 – 2000 pmol/well) and media (1.0 – 500 pmol/100µL), 
the original raw data collected for α/β-TMCA, along with the data for the other bile 
acids, was processed. The new α/β-TMCA standard curves were not generated with 
a stable isotope equivalent but were corrected for endogenous α/β -MCA 
background. Similarly, the raw data for the glycine conjugates of α- and β-muricholic 
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acid were collected but not processed in the original analytical run. Unfortunately, 
standards for these glycine conjugates are currently not available. 
 
Data Analysis. Cells + bile and cellular concentrations of bile acids were 
calculated based on estimates of hepatocyte intracellular volume (6.83 µl/well) and 
number of cells/well.243  Medium concentrations were calculated based on a volume 
of 1.5 ml/well. For bile acid accumulation studies, the in vitro biliary excretion index 
(BEI; %), defined as the percentage of accumulated substrate residing within the bile 
canaliculi, was calculated using B-CLEAR® technology (Qualyst, Inc. Durham, NC) 
according to the following equation: BEI = [(Accumulationstandard buffer -
AccumulationCalcium-free buffer)/(Accumulationstandard buffer)] X 100%.162  The in vitro biliary 
clearance (Clbile) was calculated based on the following equation: Clbile= 
(Accumulationstandard buffer – AccumulationCalcium-free buffer) / (AUCmedium), where AUC 
represents the area under the substrate concentration-time profile in the incubation 
buffer.  Statistical analyses (one-way ANOVA and Bonferroni’s multiple comparison 
post test) were performed using GraphPadPrism 3.0. In all cases, p < 0.05 was 
considered statistically significant. 
 
RESULTS 
Assessment of Cellular Viability in Sandwich-cultured Rat Hepatocytes.  
Prior studies have shown that it takes 3 days for rat hepatocytes to regain polarity in 
sandwich culture.161,244,245 Because polarity is desirable to assess bile acid transport, 
we examined the effects of 24-hr RTV and LPV treatment, alone and combined, on 
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cellular viability and bile acid disposition between culture day 3 and day 4.  LDH 
release and cellular adenosine triphospate (ATP) content were measured after 
individual and combination treatment with LPV and RTV.  Alone, LPV and RTV 
demonstrated dose-dependent effects on cellular viability; the observed differences 
between the two treatments were not significant (Figure 2.1). Toxicity was not 
detected, or was minimal, at concentrations < 50 µM for each PI.  Since toxicity may 
affect metabolic and transport processes involved in bile acid disposition in the 
SCRH model, PI concentrations < 50 µM were used in subsequent studies.  Cellular 
viability following exposure to the combination of LPV (5-50 µM) and RTV (5 µM) 
was comparable to LPV alone (Table 2.1) and the trend towards increased toxicity 
at 50 µM LPV was not statistically significant.   
[3H]TCA and [14C]CDCA Accumulation in Sandwich-cultured Rat 
Hepatocytes. Accumulation of [3H]TCA (1 µM) or [14C]CDCA (5 µM) from the culture 
medium into cells + bile vs cells alone was measured  following 10-min co-incubation 
with vehicle (0.1% DMSO), RTV (5 µM), LPV (5-50 µM), or combined LPV and RTV 
(LPV/r). As shown in Figure 2, the mean accumulation of [3H]TCA in cells + bile was 
reduced  by both LPV and RTV when administered alone, and the reduction was 
significant for LPV.  A significant reduction relative to vehicle treatment also was 
observed for the combination treatment LPV/r (from 16.0 + 2.2 vehicle alone to 7.6 + 
1.2 pmol/mg protein). It appeared that co-administration of LPV with RTV resulted in 
additional reduction in cells + bile concentration of [3H]TCA compared to LPV 
treatment alone, but this decrease was not significant.  The hepatocyte (cell) 
concentration of [3H]TCA was not significantly increased by RTV or LPV alone 
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(Figure 2.2).  However, when RTV was combined with LPV, the hepatocyte 
concentration of [3H]TCA (7.7 + 0.1 pmol/mg protein) was significantly increased 
relative to the cellular concentrations observed with either vehicle or 5 µM LPV alone  
( 5.1 + 0.7 and  5.0 + 0.5 pmol/mg protein, respectively).  When the same 
experiment was repeated with [14C]CDCA, the treatments did not significantly alter 
the accumulation of [14C]CDCA species in cells + bile or cells alone (Figure 2.3).   
Biliary excretion of [3H]TCA and [14C]CDCA in Sandwich-cultured Rat 
Hepatocytes. 
The calculated Biliary Excretion Index (BEI; %) for [3H]TCA was reduced by both 
LPV and RTV alone, and further reduced by the combination treatment (Table 2.2).  
The calculated biliary clearance values (Clbile) followed a similar pattern, but the 
reductions caused by RTV and LPV were statistically significant relative to vehicle 
treatment.  Moreover, the reduction in Clbile observed with the combination of LPV 
and RTV was significantly greater than that observed with LPV alone, suggesting an 
additive effect on impaired biliary clearance.  Concentrations exceeding 10 µM of 
LPV virtually ablated the BEI of [3H]TCA, regardless of co-administration with RTV 
(data not shown).  
[14C]CDCA cellular concentrations in vehicle treated hepatocytes were 120-
fold greater compared to [3H]TCA, and the BEI of [14C]CDCA species was 3-fold 
lower than for [3H]TCA. Thus, changes in biliary clearance may not affect the cellular 
accumulation of [14C]CDCA to the same extent as that of [3H]TCA.  LPV, alone or in 
combination with RTV reduced the BEI and essentially abolished the Clbile of 
[14C]CDCA species (Table 2.2).   
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 [3H]TCA and [14C]CDCA Initial Uptake in Suspended Rat Hepatocytes. 
To determine whether inhibition of bile acid uptake contributed to the reduction in 
Clbile caused by the PIs, [3H]TCA and [14C]CDCA influx into hepatocytes was 
measured during the linear uptake time interval (15 to 45 sec) in suspended rat 
hepatocytes 115,246.  Initial uptake rates of [3H]TCA in Na+-containing and Na+-free 
buffer were 1.53 + 0.11 and 0.15 + 0.07 pmol/sec/mg protein, respectively (n=3; 
Figure 2.4).  LPV (10 µM), RTV (5 µM), and LPV/r had no effect on the initial uptake 
rates of [3H]TCA in Na+-containing, or Na+-free buffer compared to vehicle control.   
Similarly, LPV, RTV, and LPV/r had no effect on the initial uptake rates of [14C]CDCA 
in Na+-containing and Na+-free buffer of vehicle control hepatocytes (9.92 + 3.02 and 
6.73 + 2.19 pmol/sec/mg protein, respectively; n=3; Figure 2.5). 
Accumulation of Endogenous Bile Acids in Cells + Bile, Cells, and 
Medium of Sandwich-cultured Rat Hepatocytes.  TCA, GCA, TCDCA, GCDCA, 
and α/β-TMCA were measured in cells + bile, cells, and medium of SCRH.  Taurine-
conjugated bile acids accounted for the majority (approximately 99%) of bile acid 
species detected in vehicle-treated SCRH, consistent with data from in vitro rat 
studies published previously.247  Concentrations (µM) of each bile acid species in 
cells + bile, cells, and medium of vehicle-treated SCRH are listed in Table 2.3. The 
α- and β-TMCA species comprised the majority of the total measured bile acid pool 
and appeared predominantly in the cells + bile and cells of SCRH.  The BEI value of 
endogenous TCA (49%) was in the same range as the BEI calculated following 
addition of 1 µM [3H]TCA (68%; Table 2). It is not possible to assess biliary 
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clearance of endogenously synthesized bile acids based on the current study 
design.   
Total endogenous bile acid (sum of TCA, GCA, TCDCA,  GCDCA and α/ß-
TMCA) accumulation in medium, cells, and bile of SCRH also was determined 
following 24-hr incubation with vehicle, LPV (5 or 50 µM), and RTV (5 µM), alone or 
combined. Surprisingly, all treatments, except 5 µM LPV, significantly decreased 
total bile acid accumulation compared to vehicle control by (Figure 2.6).  
Interestingly, this marked reduction in total measured bile acids occurred despite the 
observation that LPV yielded minimal apparent toxicity to SCRH at these 
concentrations (Figure 2.2). The addition of 5 µM RTV to 50 µM LPV did not further 
decrease endogenous bile acid accumulation relative to 50 µM LPV alone (Figures 
2.6-2.9).  Conversely, the addition of 5 µM RTV to low dose LPV (5 µM), significantly 
decreased both total bile acid accumulation (Figure 2.6) as well as TCDCA 
accumulation in cells + bile (Figure 2.8).  Similar trends were observed for the two 
principal bile acids measured, TCA and α/ß-TMCA (Figures 2.7 and 2.9).   
LPV (50 µM) reduced the amount of TCA in medium, cells + bile, and cells 
alone (Figure 2.7); the reductions were roughly proportional in each of these three 
compartments.  Similarly, TCDCA accumulation in cells + bile and cells alone was 
significantly decreased by 50 µM LPV; the addition of RTV did not appear to alter the 
effect of LPV alone (Figure 2.8).  Notably, the BEI of TCDCA was markedly 
decreased by RTV, alone or in combination with LPV (values at the top of Figure 
2.8).  No significant differences in the accumulation of TCDCA in the medium were 
noted.   
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 GCA accumulation in cells + bile was significantly decreased from control by 
5 µM LPV combined with 5 µM RTV (1.53 + 0.42 vs. 0.14 + 0.14 pmol/mg protein), 
and nearly abolished by exposure to high dose LPV, in the absence and presence of 
RTV.  GCDCA was essentially undetectable in cells + bile and cells of SCRH treated 
with 5 µM LPV combined with RTV, or with high dose LPV (50 µM), alone or 
combined with 5 µM RTV. Medium GCA and GCDCA were not statistically different 
following PI exposure relative to vehicle control values.  
 
DISCUSSION 
 Inhibition of BSEP-mediated biliary excretion of bile acids is a proposed 
mechanism of DILI.  Several PIs, including LPV and RTV, are inhibitors of BSEP in 
vitro and are associated with hepatotoxicity.  Moreover, HIV treatment regimens 
frequently combine RTV with other PIs to improve oral availability (boosting effect), 
and these regimens may have increased potential for liver toxicity.   The present 
work further characterizes the complex interactions between hepatocytes, PIs, and 
endogenous bile acids.  We hypothesized that addition of RTV to LPV would result 
in increased intracellular accumulation of bile acids and increased toxicity in SCRH. 
 Hepatocytes cultured in a sandwich configuration regain morphological 
properties similar to those observed in vivo, including the development of tight 
junctions, canalicular networks, and polarized transport.160  Additionally, SCRH 
exhibit toxicity when BSEP is inhibited.115,248,249  Thus, the SCRH model was 
selected as the most suitable system to evaluate the effect of the PIs, LPV and RTV, 
on cytotoxicity, bile acid transport and endogenous bile acid disposition.  
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Contrary to our hypothesis, the combination of RTV and LPV did not produce 
a detectable increase in toxicity relative to LPV alone (Table 2.1).  Nonetheless, 
exposure of SCRH to LPV coadministered with RTV further increased the cellular 
accumulation of TCA compared to LPV alone (Figure 2.2).  It is important to note 
that our transport inhibition studies were conducted after 10 min of PI exposure, 
whereas toxicity was assessed after 24 hour PI exposure. The lack of toxicity 
observed at 24 hr may indicate that normal functioning hepatocytes are capable of 
responding to cellular injury via hepatoprotective mechanisms that maintain 
hepatocyte health despite accumulation of bile acids.  Alternatively, feedback 
mechanisms could downregulate bile acid synthesis and/or upregulate bile acid 
efflux resulting in only a transient increase in intracellular bile acid concentrations.  
As expected from previous reports,78 RTV inhibited [3H]TCA Clbile and BEI.  
Exposure to LPV inhibited the Clbile of [3H]TCA, and addition of RTV resulted in 
further inhibition.  It should be noted that the marked additional reduction in [3H]TCA 
Clbile and BEI resulting from addition of RTV to LPV is consistent with additive effects 
of each drug and not a synergistic interaction.  Doubling the concentration of LPV (to 
10 µM) essentially ablated both Clbile and BEI for [3H]TCA.  This effect was similar to 
that observed when LPV (5 µM) was coadministered with RTV (5 µM). 
In contrast to the result with [3H]TCA, we were unable to detect any effect of 
LPV alone or in combination with RTV on the cellular content of [14C]CDCA species. 
This may suggest that the effects of PIs on bile acid transport are specific for certain 
bile acids.  Nonetheless, the effects of LPV and RTV on the calculated BEI and 
biliary clearance of [14C]CDCA species were similar to those observed with [3H]TCA. 
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Because the marked effects of the PIs on biliary excretion of [3H]TCA and 
[14C]CDCA species generally were not associated with similar increases in 
hepatocyte content of bile acids, it was possible that the PIs were differentially 
inhibiting basolateral uptake of bile acids.  Modulating the Na+-content of the buffer 
provides an accurate estimate of the contribution of the Na+-dependent transporter, 
Ntcp, and the sodium-independent organic anion transporting polypeptides (Oatps), 
to total uptake.  Basolateral uptake of TCA is governed primarily by Ntcp, and to a 
lesser extent by Oatps.237 Conversely, CDCA uptake is reportedly driven 
predominantly by Oatps, while Ntcp contributes to a lesser degree.242 Consistent 
with previous work, ~90% of the initial uptake rate of TCA into hepatocytes pre-
incubated with vehicle (0.1% DMSO) was Ntcp-mediated, while the remaining ~10% 
was driven by sodium-independent transporter-mediated processes (presumably 
Oatps). Conversely, ~69% of transporter-mediated [14C]CDCA uptake occurred in 
Na+-free buffer, consistent with the literature findings that Oatp transporters are 
primarily responsible for initial CDCA uptake.242,250  LPV and RTV, alone and 
combined, had no significant effect on the initial uptake of [3H]TCA or [14C]CDCA 
under Na+-containing and Na+-free conditions.  Based on these findings, we 
concluded that disruption of canalicular efflux is the primary mechanism responsible 
for the PI-mediated decrease in the biliary clearance of [3H]TCA and [14C]CDCA.      
Reported in this manuscript, for the first time, are the effects of PIs on the 
disposition of bile acids synthesized by SCRH.  While the bile acid pool is comprised 
of numerous bile acid species, the present study focused on the quantification of 
taurine- and glycine-conjugated cholic acid and chenodeoxycholic acid  due to their 
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potential cytotoxic effects.119,251,252  In addition, the aforementioned bile acids are 
common constituents of both human and rodent bile.  The rodent-specific α/ß-TMCA 
species also were quantified since they make up the majority of the bile acid pool in 
the rat. Secondary bile acids, i.e. those produced via intestinal metabolism, are not 
synthesized in the SCRH system; thus, these bile acid species were not 
quantified.120  BEI values for endogenous TCA were comparable to those estimated 
following addition of radiolabelled TCA.  However, very different results were 
obtained when we investigated the effects of the PIs on intracellular concentrations 
of endogenously synthesized TCA.  Contrary to our results with exogenous [3H]TCA 
administration and short-term PI exposure, RTV and LPV treatment (5 and 50 µm; 
24 hr) resulted in a significant reduction in hepatocyte concentrations of endogenous 
TCA and α/ß-TMCA.  Addition of RTV to high dose LPV (50 µM) appeared to have 
little additive effect. However, addition of RTV to low dose LPV (µM) significantly 
reduced the accumulation of endogenously synthesized total bile acids and TCDCA 
in SCRH (Figures 2.6 and 2.8). This observation may indicate that RTV inhibits LPV 
metabolism leading to increased cellular LPV concentrations, which may result in 
altered bile acid synthesis. These studies suggest that LPV and RTV may alter the 
synthesis and biliary excretion of individual bile acids differentially.  
Fresh medium was applied to the SCRH every 24 hours. Thus, the 
remarkable decrease in total measured bile acid content may be due to reduced bile 
acid synthesis.  Consistent with this conclusion, RTV (15-100 µM) exposure for 24 hr 
has been reported to disrupt cholesterol homeostasis and perturb bile acid synthesis 
in a concentration-dependent manner by decreasing the activity of cholesterol 7α 
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hydroxylase, the rate-limiting enzyme responsible for the catabolism of cholesterol to 
bile acids.253  Based on these findings, the observed decrease in total measured bile 
acids following PI exposure in SCRH probably involves regulatory feedback 
mechanisms that promptly reduce synthesis of bile acids as a protective mechanism.  
An important conclusion drawn from our studies is that it may be necessary to 
quantify hepatocellular concentrations of endogenous bile acids when establishing a 
relationship between drug-mediated inhibition of hepatic transporters and 
hepatotoxicity.   
An important question is how the effects of LPV and RTV on bile acid 
excretion from hepatocytes may relate to the hepatotoxicity observed in the clinic 
with these drugs.  At steady-state, LPV and RTV are 98-99% bound to plasma 
proteins, albumin, and AAG.  The average unbound fraction of LPV was 0.73% and 
ranged from 0.14-1.68%.254   Total and unbound LPV concentrations in HIV-infected 
patients ranged from 677 to 23,767 ng/ml (~1-38 µM) and 4.2 to 209.2 ng/ml (0.007-
0.33 µM), respectively.  PI concentrations selected for these studies exceeded 
reported unbound plasma concentrations by 10-fold or more.  However, pilot data 
indicated that intracellular LPV concentrations in SCRH were up to 20-fold greater 
than medium concentrations after co-administration with RTV (data not shown).   
In summary, we found that short term exposure of hepatocytes to LPV and 
RTV resulted in reduced biliary excretion and, consequently, intracellular 
accumulation of TCA. However, following 24 hr exposure to LPV and RTV, we were 
unable to demonstrate even additive toxicity, and we observed a marked reduction 
in hepatocyte accumulation of endogenous bile acids (sum total of TCA, GCA, 
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TCDCA, GCDCA and α/ß-TMCA), primarily attributed to decreased α/ß-TMCA.  
These observations do not necessarily refute a role for bile acid transport inhibition 
in the DILI observed in patients treated with PIs. This is because most patients 
treated with PIs do not develop hepatotoxicity.  We speculate that initial PI-mediated 
increases in cellular bile acid concentrations initiate a cascade of events that 
enables the hepatocytes to remain healthy in most patients.  This adaptive response 
includes mechanisms that result in a marked decrease in hepatocyte content of bile 
acids, most likely involving reduced synthesis.   We further speculate that this 
adaptive response may not occur in all patients treated with these drugs. If such 
deficiencies have a genetic basis, their identification could lead to a personalized 
medicine approach to avoid DILI in PI-containing regimens.   
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Table 2.1 Effect of 24-hour lopinavir exposure, in the presence or absence of 
ritonavir, on sandwich-cultured rat hepatocyte viability. 
 
 LPV LPV/r 
 Viability (% Control) 
Dose 
(µM) 
LDH 
assay 
ATP 
assay 
LDH 
assay 
ATP 
assay 
5 99 + 1 102 + 15 99 + 1 81 + 7 
10 100 + 1 105 + 7 99 + 1 80 + 7 
25 99 + 1 101 + 1 98 + 1 79 + 4 
50 98 + 2 81 + 22 88 + 8 68 + 25 
 
Notes. Day 3 sandwich-cultured rat hepatocytes were treated for 24 hr with lopinavir 
(LPV) in the absence or presence of ritonavir (LPV/r); mean ± SEM (n=3 livers in 
triplicate). 
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Table 2.2 Effect of lopinavir and ritonavir on the biliary excretion index and in vitro 
biliary clearance of [3H]taurocholic acid and [14C]chenodeoxycholic acid  in 
sandwich-cultured rat hepatocytes. 
 
 BEI (%) Clbile (ml/min/kg) 
 [3H]TCA [14C]CDCA [3H]TCA [14C]CDCA 
Vehicle  68 + 3 27 + 2 8.7 + 1.3 37.2 + 8.1 
5 µM RTV  21 + 15 3 + 3 2.5 + 2.1a 0 
5 µM LPV  49 + 11 4 + 4 4.4 + 1.7a 0 
5 µM LPV/r  9 + 5 1 + 1 0.61 + 0.35b 0 
 
Notes. Data from Figures 2 and 3 were used to calculate the biliary excretion index 
(BEI) and in vitro biliary clearance (Clbile), as described in the methods, in the 
absence or presence of RTV (LPV/r); mean ± SEM (n=3 livers in triplicate, analysis 
of variance followed by a Bonferroni post test; a, versus vehicle control; b versus 5 
µM LPV alone, p < 0.05). 
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Table 2.3 Bile acid concentrations (µM) in cells + bile, cells, and medium, and biliary 
excretion index values for each bile acid species, in day 4 sandwich-cultured rat 
hepatocytes. 
 
Species  Cells + bile Cells Medium BEI (%) 
TCA  5.14 + 1.71 2.61 + 1.78 0.651 + 0.127 49 
GCA  0.20 + 0.06 0.13 + 0.08 0.07+ 0.03 35 
TCDCA  1.07 + 0.20 0.63 + 0.20 0.017 + 0.003 41 
GCDCA 0.12 + 0.08 0.07 + 0.04 0.004 + 0.003 42 
α/ß TMCA 168 ± 65 133  ± 72 1.59 ± 0.37 20 
Total 174 ± 67 137 ± 74 2.34 ± 0.412 
 
Notes. Data represent mean ± SEM (n=3 livers in triplicate). Calculations assume a 
hepatocyte volume of 6.83 µl/well.  The biliary excretion index (BEI) was calculated 
as described in the methods.  
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Figure 2.1 Effect of 24-hr exposure to LPV or RTV on hepatocyte viability in 
sandwich-cultured rat hepatocytes (SCRH).  Day 3 SCRH were treated with LPV 
(squares; 5-100 µM) or RTV (triangles; 5-100 µM) for 24 hours. Following 
incubation, LDH release (A) and cellular ATP (B) levels were measured.  Data are 
presented as mean + SEM (n =3).   
A      B 
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Figure 2.2 Effect of LPV and RTV, alone and combined, on taurocholic acid (TCA) 
accumulation in SCRH. [3H]TCA BEI and accumulation in cells + bile (black bars) 
and cells (white bars), in day 4 SCRH were determined following a 10-min co-
incubation with ritonavir (RTV, 5 µM) and lopinavir (LPV; 5 µM) alone or combined 
(LPV/r) (mean + SEM; n = 3 livers in triplicate;
 
analysis of variance followed by a 
Bonferroni post test , * versus cells + bile vehicle control, # vs. 5 µM LPV alone; p < 
0.05). 
 83 
 
 
Figure 2.3 Effect of LPV and RTV, alone and combined, on chenodeoxycholic acid  
(CDCA) accumulation in SCRH. [14C]CDCA BEI and accumulation in cells + bile 
(black bars) and cells (white bars), in day 4 SCRH were determined following a 10-
min co-incubation with ritonavir (RTV; 5 µM) and lopinavir (LPV; 5 µM) alone or 
combined (LPV/r) (mean + SEM; n = 3 livers in triplicate).  
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Figure 2.4 Effect of LPV and RTV, alone and combined, on the Na+-dependent and 
Na+-independent uptake of [3H]TCA into freshly isolated suspended rat hepatocytes. 
[3H]TCA accumulation in freshly isolated rat hepatocytes was determined following 
pre-incubation with LPV (10 µM; A) or RTV (5 µM; B), alone and in combination (C), 
in the absence or presence of sodium.  Closed and open circles represent vehicle 
treated cells in Na+-containing or Na+-free buffer, respectively. Closed and open 
triangles represent treated cells in Na+-containing or Na+-free buffer, respectively.  
Uptake into cells is reported as pmol/ mg protein (mean + SEM; n=3 livers in 
triplicate).  
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Figure 2.5 Effect of LPV and RTV, alone and combined, on the Na+-dependent and 
Na+-independent uptake of [14C]CDCA into freshly isolated suspended rat 
hepatocytes. [14C]CDCA accumulation in freshly isolated rat hepatocytes was 
determined following pre-incubation with LPV (10 µM; A) or RTV (5 µM; B) alone 
and in combination, in the absence or presence of sodium (C).  Closed and open 
circles represent vehicle treated cells in Na+-containing or Na+-free buffer, 
respectively. Closed and open triangles represent treated cells in Na+-containing or 
Na+-free buffer, respectively.  Uptake into cells is reported as pmol/ mg protein 
(mean + SEM; n=3 livers in triplicate). 
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Figure 2.6 Accumulation of total measured bile acids (sum of TCA, GCA, TCDCA,  
GCDCA, and α/ß-TMCA) in SCRH (cells, bile, and medium) following 24-h treatment 
with vehicle (0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined 
(mean + SEM; n=4 livers in triplicate;
 
analysis of variance followed by a Bonferroni 
post test, *,
 
versus vehicle control, p < 0.05). 
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Figure 2.7 Accumulation of TCA in cells + bile (solid bars), cells (open bars), and 
medium (hatched bars) and BEI values in SCRH following 24-h treatment with 
vehicle (0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined (mean 
+ SEM; n=4 livers in triplicate;
 
analysis of variance followed by a Bonferroni post 
test, *,
 
versus vehicle control, p < 0.05). 
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Figure 2.8 Accumulation of TCDCA in cells + bile (solid bars), cells (open bars), and 
medium (hatched bars) and BEI values in SCRH following 24-h treatment  with 
vehicle (0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined (mean 
+ SEM; n=4 livers in triplicate;
 
analysis of variance followed by a Bonferroni post 
test, *,
 
versus vehicle control; #, versus 5 µM LPV, p < 0.05) 
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Figure 2.9 Accumulation of α/ß-TMCA in cells + bile (solid bars), cells (open bars), 
and medium (hatched bars) and BEI values in SCRH following 24-h treatment  with 
vehicle (0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined (mean 
+ SEM; n=4 livers in triplicate;
 
analysis of variance followed by a Bonferroni post 
test, *,
 
versus vehicle control; #, versus 5 µM LPV, p < 0.05) 
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CHAPTER 3 
GENETIC VARIATION IN BILE ACID TRANSPORT AND SYNTHESIS GENES: A 
POTENTIAL RISK FACTOR FOR DRUG-INDUCED LIVER INJURY 
 
 Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the 
United States and is the most common adverse event leading to the withdrawal of 
drugs from the market.255-257  DILI is rare, which makes predicting hepatotoxic 
events associated with drug therapy challenging.  Impaired bile acid transport 
leading to the accumulation of bile acids known to cause mitochondrial damage and 
decreased membrane integrity is a proposed mechanism of DILI.77,114,258 The bile 
salt export pump (BSEP) is the primary transport protein responsible for the 
canalicular excretion of bile acids.126,128,259,260  Increasing evidence in the literature 
has established a correlation between inhibition of BSEP and cholestasis.124,159,258  
However, numerous studies demonstrate drug- and/or cholestasis-induced 
upregulation of alternate bile acid elimination pathways, and changes in the 
expression and activity of enzymes involved in bile acid synthesis.  These changes 
in feedback regulatory mechanisms may offer hepatoprotection against the cellular 
accumulation of bile acids.87,88,130,135,253    For example, a seven-fold increase in the 
protein expression of the multidrug resistance-associated protein (MRP) 4, which 
facilitates basolateral efflux of an array of compounds including bile acids, has been 
reported in cholestasis-induced bile duct ligated rats.87  
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Drugs can also indirectly affect bile acid synthesis and transport. Ritonavir, a 
potent inhibitor of BSEP, has been shown to significantly decrease cytochrome P450 
(CYP)7A1 mRNA and protein expression levels in primary rat hepatocytes.  CYP7A1 
is the rate-limiting enzyme responsible for the conversion of cholesterol to bile acids.  
In the same study, bile acid synthesis also was decreased following exposure to 
ritonavir.253   
 Bile acids are taken up from the systemic circulation into the hepatocyte 
largely by the sodium-dependent co-transporting polypeptide (NTCP).  NTCP is a 
member of the solute carrier (SLC) family, and is primarily responsible for the uptake 
of monovalent taurine- and glycine-conjugated bile acids.  Sulfated compounds, 
thyroid hormones and a few drugs are also substrates for NTCP.128  Organic anion 
transporting polypeptides (OATPs) mediate the sodium-independent basolateral 
uptake of bile acids.  Two liver-specific isoforms, OATP1B1 and -1B3 contribute to 
the influx of bile acids and endogenous compounds such as bilirubin.   While 
transporter affinity varies between bile acids species, the sodium-dependent uptake 
of bile acids is quantitatively more important in humans than the sodium-
independent uptake processes.128,242  
 Canalicular efflux, the rate-limiting step in hepatocellular transport of bile 
acids, is driven predominantly by BSEP and thus, this protein is the focus of the 
present study.128  The importance of BSEP in bile acid homeostasis has been 
demonstrated repeatedly in the literature.  Decreased mRNA and protein levels of 
BSEP in liver slices incubated with lipopolysaccarides from patients with 
inflammatory liver disease have been reported by Elfereink and colleagues.232  
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Administration of ursodeoxycholic acid, used to treat cholestasis, is associated with 
upregulation of BSEP in patients with gallstones.261  Genetic mutations in BSEP 
resulting in cholestatic diseases in humans also have been reported.  One of the 
most severe diseases associated with a polymorphism in BSEP is progressive 
familial intrahepatic cholestasis type 2 (PFIC2).  Clinical presentation often begins 
during childhood and usually progresses to severe cholestasis warranting liver 
transplantation.130,262,263 
 Other transporters located on the canalicular membrane play a minimal role in 
the efflux of some bile acids.  MRP2 excretes sulfated and glucuronidated bile acids 
as well as bilirubin into the bile, while p-glycoprotein (P-gp) transports taurine- and 
glycine-conjugated bile acids.120,137,264  However, these proteins are primarily 
responsible for the canalicular efflux of a diverse range of drugs, including 
compounds that interact with BSEP.    
Basolateral efflux transporters MRP3 and MRP4 are expressed at low levels 
in healthy hepatocytes.   While these proteins generally contribute to the basolateral 
efflux of numerous, structurally diverse drugs, MRP3- and MRP4-mediated bile acid 
transport has been shown.137,140,141  Furthermore, MRP3 and MRP4 may be 
upregulated during cholestasis as a hepatoprotective mechanism.  Increased renal 
excretion of bile acids in patients with chronic cholestasis corroborates this 
observation.139,265,266  The organic solute transporter (OST) α, combined with OSTß, 
transports bile acids in a sodium-independent fashion.  OSTα is modestly expressed 
in the human liver while OSTß liver expression is virtually undetectable.   While the 
independent function of each subunit has yet to be determined, it is clear that co-
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expression and assembly is required for trafficking of this protein to the plasma 
membrane.  The localization of proteins involved in hepatic bile acid transport is 
depicted in Figure 3.1.  
The mechanisms underlying DILI are complex and most likely involve a 
number of factors including, age, gender, duration of drug exposure, concomitant 
medications, and co-morbidities.  Several studies also suggest that genetic variants 
in specific transport proteins may alter the disposition of drugs and endogenous bile 
acids, thereby predisposing some individuals to drug-induced 
hepatotoxicity.130,149,153,267-269  In addition, genes involved in bile acid synthesis can 
indirectly influence bile acid transport.  Thus, deleterious genetic mutations in such 
genes may indirectly contribute to the risk of DILI.   Based on this rationale, we 
tested the hypothesis that single nucleotide polymorphisms (SNPs) in genes that 
play a role in bile acid transport and synthesis are predictive risk factors for DILI. 
Furthermore, multiple variants in genes that serve as alternate routes of bile acid 
excretion may have an additive effect on the risk of DILI.   
 
METHODS  
Study Subjects 
Polymorphisms in candidate genes selected based on literature review were 
used to conduct a SNP association analysis to elucidate the role of genetic variants 
in DILI.  After patients provided informed consent, DNA samples were obtained and 
prepared as reported previously.270,271 Cases (n=401) of European ancestry enrolled 
in the Drug-induced Liver Injury Network (DILIN)270 between August 2004 and April 
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2009 were included in the study.   Cases were genotyped at the Duke Center for 
Human Genome Variation using the Illumina Human1M-Duo BeadChip.  Genotype 
data from 2,346 controls from the 1958 British Birth Cohort supplied by the 
Wellcome Trust Case-Control Consortium 2 (www.wtccc.org.uk) were used for 
comparison.  Cases were categorized as hepatocellular, cholestatic or mixed using 
the R value as described by Danan et al.272  Severity of hepatic injury (ranging from 
mild to fatal) and causality scores also were determined.270  Characteristics of the 
DILIN patients included in the present study are listed in Table 3.1  
 
Selection and Analysis of Genetic Variants. 
In the present study, variants in genes implicated in bile acid metabolism and 
hepatobiliary transport were selected for analysis. The genetic variants were chosen 
from a subset of drug absorption, distribution, metabolism and elimination (ADME) 
genes for which genotyping data were previously generated in a genome-wide 
association analysis.270,271  The majority of the selected variants were located in 
exomic regions. Two variants were located at the 5’ or 3’ untranslated region, and 
seven variants were located in intronic regions.  Although some SNPs were selected 
based on reported functional consequences, to date, evidence demonstrating 
functional roles of genetic variants, particularly for drug transporters, is limited.   
Table 3.2 lists the SNPs and genes selected, their physiological function, associated 
phenotypes (where clinically reported), and genomic location.  
To evaluate potential associations of individual variants with DILI, genotypes 
were analyzed as wild-type versus variant carriers, where variant carriers were 
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either heterozygotes or homozygotes.  Logistic regression analyses were performed 
to evaluate the relationship between individual polymorphisms and DILI in wild-type 
and variant carriers.   Studies examining the influence of multiple MRP3 and MRP4 
variants on DILI cases involving drugs known to inhibit BSEP238 also were analyzed 
using logistic regression. All tests were carried out using the top 10 principal 
components emerging from the EIGENSTRAT analyses273 as covariates in the 
model.  Drugs reported to inhibit BSEP that were suspected of causing liver toxicity 
in the DILIN cases are listed in Table 3.3. The outcome was dichotomized based on 
the absence or presence of DILI, and the number of variants present in MRP3 
and/or MRP4 was counted. The specified threshold for significance after multiple 
test correction was p < 0.001.  All hypotheses tested were determined a priori.  
 
RESULTS 
A total of 30 out of 36 selected variants were analyzed by logistic regression.  
Four variants were omitted from the analysis because they were present only in a 
small number of controls, which caused collinearity problems in the regression; 
these variants were found in MRP4 (rs11568668), OSTα (rs9849888) and OSTß 
(rs2919347 and rs4961295).  Additionally, CYP7A1 (rs8192875) and SREBF2 
(rs2229440) variants were only found in one individual.  Consequently, there was not 
sufficient data to perform logistic regression analysis for these variants.  Odds ratios, 
p-values and 95% confidence intervals for each comparison are listed in Table 3.4.  
Quantile-quantile plots were constructed for each analysis to evaluate the 
distribution of each variant (Figures 3.2, 3.3 and 3.4).  Generally, the distribution of 
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p-values resulting from the set of tests performed were no different from those 
expected under the null hypothesis.  None of the individual variants assessed were 
significantly associated with an increased risk of DILI when controls were compared 
to all DILI cases, or when controls were compared to cholestatic cases.  However 
the association of the OSTß variant, rs2919351, was notable when controls were 
compared to all DILI cases and cholestatic DILI cases (odds ratios of 3.6 and 6.1, 
respectively).  The rs2919351 variant yielded a significantly increased odds ratio of 
10.1 (p<0.0015) when controls were compared to cholestatic and mixed DILI cases. 
This odds ratio was greater for mixed cases alone (17.6, p=3 X 10-4). It is important 
to note that this variant clearly deviates from the expected distribution for the 
cholestatic and mixed model (Figure 3.4). We next examined whether the 
association would strengthen with increased confidence in the diagnosis of DILI.  
Cases without causality scores and those with scores of “unlikely” and “possible” 
were omitted from the analysis.  We found that the odds ratio and strength of 
association were modestly decreased when the analysis was restricted to confirmed 
probable cases (Table 3.5).         
Because MRP3 and MRP4 may compensate for loss of BSEP activity in the 
setting of BSEP inhibition, we hypothesized that individuals carrying variants in 
MRP3 and/or MRP4 may be at increased risk of DILI due to BSEP inhibiting drugs, 
and that the risk may be additive with increasing burden of MRP3/4 variants.  Of the 
401 cases, approximately 12% of the indicated drugs have been reported to inhibit 
BSEP (Table 3.3).  Logistic regression analysis of 49 DILI cases due to known 
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BSEP inhibitors and 2,346 controls revealed no significant differences in risk of DILI, 
irrespective of DILI category.  
 
DISCUSSION  
Our hypothesis was that variations with functional consequences in genes 
involved in bile acid transport and synthesis may influence the risk of drug-induced 
hepatotoxicity.  The present study investigated the impact of genetic variants on the 
risk of DILI.  Additionally, the hypothesis that multiple variants in transporter genes 
that act as compensatory elimination routes (i.e. MRP3 and MRP4) have an additive 
effect on the risk of DILI was examined.  We found that the OSTß variant rs2919351 
was associated with cholestatic and mixed DILI, and that this association 
approached significance even after correction for multiple comparisons.  Moreover, 
this association achieved significance when only mixed DILI cases were examined. 
This observation suggests that this variant in OSTß may increase patient 
susceptibility to hepatotoxic events following drug exposure. Secondary analysis in 
which cases with less evidence of causality were omitted showed no differences in 
the variant contribution to DILI. The observation that the association was strongest 
with mixed rather than cholestatic DILI could be explained by the theory that DILI is 
a progressive adverse event in which hepatocellular death is preceded by 
cholestasis.  Thus, “mixed” DILI may, in fact, be the result of cholestasis and 
ultimately progression to hepatocellular liver injury. 
Since the phenotypic outcome of interest (DILI) is a rare event, population 
controls (rather than drug-treated controls) were chosen for comparison to DILI 
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patients. The present study was a retrospective, hypothesis-driven investigation that 
was exploratory in nature, and as such, there are obvious limitations. Firstly, only 
subjects of European descent were included in the analysis.  Although this restriction 
creates a population that is not representative of the general North American 
population, it does eliminate the risk of spurious findings due to population 
stratification.  Also, variants selected for interrogation were restricted to those 
genotyped or tagged on the Illumina 1Mduo BeadChip, which generally only 
contains polymorphisms with allelic frequencies of at least 5%.  As a result, we were 
unable to characterize the influence of more rare genetic variants on DILI. It is often 
assumed that variants that are apt to markedly affect transporter and enzyme 
function are likely to be deleterious and subject to purifying selection, and are 
therefore expected to be rare in the population. This concept has been 
demonstrated for transporter genes in particular.274,275  Studies clearly demonstrating 
a functional consequence of genetic variants on genes involved in drug and/or bile 
acid disposition, particularly those in transporter genes, are limited.  Thus, it is 
unclear whether some of the SNPs selected in the present study have a notable 
influence on the hepatic disposition of bile acids in humans.  A final limitation is that 
information regarding which drugs inhibit BSEP in humans is minimal.  Cases 
involving BSEP inhibitors were selected based on evidence in the literature.  
Consequently, compounds that inhibit BSEP but lack data supporting this interaction 
were not included in the BSEP-focused association analysis. 
In conclusion, a variant in the basolateral bile acid efflux transporter, OSTß 
significantly increased the risk of cholestatic and mixed DILI.  If confirmed in 
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additional cohorts, this finding supports our hypothesis that genetic variants in bile 
acid transporters and metabolic enzymes might contribute to the disposition of 
endogenous bile acids, thereby increasing the risk of DILI.  Further studies are 
warranted to understand the potential role of rare variants, characterize the 
functional consequences of individual variants, and examine the contribution of 
putatively functional variants to drug-induced hepatotoxicity. 
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 Figure 3.1 Illustration of hepatic transport proteins involved in bile 
acid transport in humans.  Basolateral uptake of bile acids is 
governed primarily by NTCP, and to a lesser extent by OATPs. 
Canalicular efflux of bile acids is facilitated by BSEP, which 
represents the rate-limiting step in the hepatocellular disposition 
of bile acids.  MRP3 and MRP4 are basolateral drug transporters 
that are capable of effluxing bile acids under cholestatic 
conditions.  The OSTα/OSTß heterodimer, while predominantly 
expressed in the intestine, contributes to the basolateral efflux of 
bile acids from hepatocytes.  P-gp and MRP2 are responsible for 
the canalicular efflux of an array of drugs and endogenous 
compounds (e.g., bilirubin). However, modest canalicular efflux of 
taurine- and glycine-conjugated (P-gp) as well as sulfated 
(MRP2) bile acids has been demonstrated. 
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Figure 3.2 Normal probability plot of all DILI cases. 
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Figure 3.3 Normal probability plot of cholestatic DILI cases. 
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Figure 3.4 Normal probability plot of cholestatic and mixed DILI cases. 
 
 104 
 
Table 3.1 DILIN subject characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
 
N.D.: not determined
Variable  DILIN patients, N (%) 
Gender   
     Male  159 (40) 
     Female  241 (60) 
DILI Category  
     Cholestatic 82 (21) 
     Hepatocellular 158 (40) 
     Mixed  80 (20) 
     N.D. 60 (15) 
Severity   
     Mild  105 (26) 
Moderate  80 (20) 
     Moderate-hospitalized 47 (12) 
     Severe  20 (5) 
     Fatal  124 (31) 
     N.D. 24 (6) 
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Table 3.2 Genes and SNPs interrogated 
 
 
 
Gene Function 
dbSNP and 
location 
Associated Phenotype/ 
Functional Evidence 
BSEP Canalicular efflux of bile 
acids. 
rs2287622a ↑risk of ICP269, CC, DC, BRIC267 
rs497692b PBC; Severe exon skipping267 
rs4148777b N.R. 
MRP2 Canalicular efflux of organic 
anions, including drugs and 
some endogenous 
compounds. 
rs2273697a ↓ affinity for LTC4, E23G, and E217G in Sf9 transfected cells 
↓ carbamazepine transport276,277 
rs8187707b N.R. 
rs8187710a ↑LPV accumulation in PBMCs of HIV-infected patients276 
MRP3 Basolateral efflux of organic 
anions, including drugs and 
endogenous compounds 
such as bile acid conjugates 
(under cholestatic 
conditions). 
rs4794175c N.R. 
rs11568605a N.R. 
rs4148416b N.R. 
rs11568591a N.R. 
rs2277624b N.R. 
rs11568589b N.R. 
rs1051640b N.R. 
MRP4 Basolateral efflux of drugs 
and endogenous compounds, 
including bile acids (under 
cholestatic conditions). 
rs3742106d N.R. 
rs3765534a ↓ surface membrane protein expression278; 
↑ sensitivity to 6-mercaptopurine toxicity278 
rs11568668a ↑ intracellular levels of azidothymidine and PMEA279 
rs11568658a ↑ intracellular levels of azidothymidine and PMEA279 
P-gp 
 
 
 
 
Canalicular efflux of drugs 
and some endogenous 
compounds (e.g. bilirubin).  
rs2235035c ↑ susceptibility to colorectal cancer280 
rs1128503b ↑ exposure and  ↓ clearance of doxorubicin281; 
↑ systemic tipifarnib exposure in cancer patients282 
rs1202168c Altered menopausal hormone replacement-associated colorectal 
cancer risk283 
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N.R.: not reported; CC: contraception-induced cholestasis; DC: drug-induced cholestasis; BRIC: benign recurrent extrahepatic 
cholestasis; PBMC: peripheral blood mononuclear cells; ICP: intrahepatic cholestasis of pregnancy; PFIC: progressive familial 
intrahepatic cholestasis; LTC4: cysteinyl leukotriene; E23G:Estradiol-3-glucuronide; E217G: Estradiol-17-beta-
Gene 
Function 
dbSNP and 
location 
Associated Phenotype/ 
Functional Evidence 
P-gp 
 
Canalicular efflux of drugs 
and some endogenous 
compounds (e.g. bilirubin). 
rs3789243c ↑ drug resistance in epilepsy patients284 
rs3213619e ↓mRNA expression in colorectal cancer cells285; ↓tacrolimus 
systemic concentrations286 
OSTα Basolateral efflux of bile 
acids. 
 
rs11719281b N.R. 
rs1522394b N.R. 
rs939885a N.R. 
rs17852687b N.R. 
rs9849888a N.R. 
                                                                                        
OSTß 
Basolateral efflux of bile 
acids. 
rs2414870c N.R. 
rs2919347c N.R. 
rs34961295c N.R. 
rs2919351c N.R. 
CYP7A1 
 
Rate-limiting enzyme in the 
classical pathway of bile acid 
synthesis. 
rs8192875a N.R. 
CYP39A1 Enzyme involved in the 
conversion of cholesterol to 
bile acids. 
rs2277119a N.R. 
HSD3B7 
 
Enzyme involved in the 
conversion of cholesterol to 
bile acids. 
 
rs9938550a PFIC type 4287 
rs34212827a N.R. 
SREBF2 Transcription factor that 
regulates cholesterol 
homeostasis. 
rs2229440a 
 
N.R. 
 
106
 
 107 
 
glucuronide; PMEA: para-methoxyethylam1phetamine; a: coding non-synonymous missense mutation; b: synonymous mutation; 
c:intron; d: 3 prime untranslated region; e: 5 prime untranslated region.  
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                   Table 3.3 List of BSEP Inhibitors Implicated in DILI cases 
Implicated Drug # of Cases 
Amiodarone 3 
Amitriptyline Hydrochloride 1 
Ciprofloxacin 5 
Cylophosphamide 2 
Erythromycin 1 
Estradiol 1 
Fluconazole 2 
Fluoxetine 2 
Glipizide 1 
Isoniazid 16 
Metformin 2 
Methotrexate 2 
Metoprolol 1 
Nevirapine 2 
Ranitidine 2 
Simvastatin 4 
Tizanidine 1 
Verapamil 1 
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Table 3.4 Logistic Regression Analysis of Controls versus DILIN Cases 
  All Cases (n=401) Cholestatic (n=82) Cholestatic/mixed (n=162) 
  
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
BSEP rs497692 1.1 0.210 0.940 1.325 1.2 0.337 0.840 1.664 1.2 0.161 0.930 1.546 
 rs2287622 0.9 0.431 0.783 1.110 0.9 0.396 0.601 1.223 0.9 0.591 0.721 1.205 
 rs4148777 1.4 0.098 0.940 2.074 1.4 0.325 0.698 2.963 1.2 0.632 0.634 2.119 
MRP2 rs2273697 0.8 0.013 0.599 0.942 0.8 0.379 0.535 1.269 0.8 0.182 0.579 1.109 
 rs8187707 1.2 0.388 0.825 1.641 1.2 0.608 0.609 2.337 1.1 0.754 0.648 1.820 
 rs8187710 1.2 0.428 0.814 1.625 1.2 0.575 0.618 2.377 1.0 0.897 0.610 1.756 
MRP3 rs4794175 1.1 0.488 0.817 1.526 1.2 0.644 0.619 2.171 1.4 0.152 0.890 2.118 
 rs11568605 0.1 0.028 0.011 0.773 N.A. 0.2 0.196 0.017 2.310 
 rs4148416 1.3 0.131 0.923 1.857 1.3 0.441 0.660 2.601 1.3 0.254 0.809 2.236 
 rs11568591 0.9 0.499 0.622 1.260 1.3 0.363 0.726 2.397 1.0 0.911 0.593 1.595 
 rs2277624 1.0 0.991 0.814 1.232 0.9 0.795 0.623 1.436 1.0 0.772 0.701 1.302 
 rs11568589 1.0 0.947 0.408 2.609 N.A. N.A. 
 rs1051640 1.0 0.703 0.763 1.200 0.8 0.333 0.491 1.272 0.9 0.659 0.664 1.296 
MRP4 
rs3742106 1.0 0.591 0.880 1.252 0.9 0.626 0.644 1.304 1.0 0.740 0.738 1.241 
rs3765534 0.8 0.674 0.328 2.057 1.2 0.854 0.259 5.111 0.5 0.420 0.120 2.419 
rs11568658 1.8 0.022 1.091 2.997 2.5 0.026 1.117 5.777 1.7 0.134 0.843 3.604 
P-gp rs2235035 1.0 0.957 0.830 1.193 0.8 0.189 0.560 1.122 0.9 0.476 0.697 1.183 
 rs1128503 1.1 0.297 0.923 1.299 1.1 0.541 0.793 1.557 1.3 0.060 0.990 1.644 
 rs1202168 1.1 0.222 0.938 1.319 1.1 0.423 0.819 1.609 1.3 0.051 0.999 1.658 
 rs3789243 1.0 0.689 0.818 1.142 0.9 0.467 0.634 1.232 0.8 0.113 0.640 1.048 
 rs3213619 1.3 0.196 0.869 1.987 0.4 0.211 0.128 1.576 1.3 0.447 0.688 2.334 
OSTα rs11719281 1.1 0.659 0.822 1.363 1.0 0.986 0.606 1.635 1.0 0.938 0.700 1.471 
 rs1522394 1.1 0.350 0.903 1.334 1.1 0.758 0.725 1.556 1.0 0.822 0.775 1.379 
 rs939885 1.0 0.899 0.835 1.171 1.0 0.979 0.720 1.402 1.1 0.367 0.874 1.439 
 rs17852687 1.2 0.089 0.978 1.374 1.3 0.171 0.905 1.759 1.1 0.528 0.845 1.389 
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  All Cases (n=401) Cholestatic (n=82) Cholestatic/mixed (n=162) 
  
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
Odds 
Ratio 
p 
value 
95% 
Confidence 
Interval 
OSTß rs2414870 1.0 0.953 0.787 1.289 0.9 0.646 0.534 1.476 0.9 0.688 0.637 1.346 
 rs2919351 3.6 0.078 0.868 14.824 6.1 0.114 0.649 57.703 10.1 0.001 2.519 40.325 
CYP39A1 rs2277119 0.9 0.144 0.697 1.054 0.8 0.236 0.510 1.180 0.8 0.108 0.565 1.058 
HSD3B7 rs9938550 1.0 0.637 0.803 1.144 0.9 0.478 0.616 1.254 1.0 0.939 0.781 1.306 
 rs34212827 1.4 0.604 0.427 4.316 4.3 0.040 1.070 17.309 2.3 0.247 0.566 9.177 
N.A.: Not Applicable
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Table 3.5 Secondary Analysis of rs2919351: Influence of DILI Category and 
Causality                                                                                     
 
 
Odds 
Ratio 
 
 
p value 
95% 
Confidence 
Interval 
Control vs. mixed DILIa 17.6 0.000344 3.67 84.79 
Control vs. cholestatic + mixed DILI 10.1 0.001075 2.52 40.33 
Control vs. cholestatic + mixed DILIb 9.7 0.003000 2.19 42.64 
astatistically significant 
bcases restricted to those with causality scores > probable
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
Drug-induced liver injury (DILI) is a rare but severe adverse event, often resulting in 
the withdrawal of otherwise effective drugs from the market.255,257  DILI accounts for 
at least 13% of US acute liver failure cases256 and the incidence of DILI reportedly 
ranges from one in 10,000 to one in 100,000 patients on medications.288 
Unfortunately, the number of DILI-inducing drugs that have known mechanisms of 
toxicity and/or exhibit dose-dependent toxicity is marginal.  Furthermore, not all 
drugs that elicit abnormal liver function tests cause patients to develop persistent 
hepatotoxicity.  Several examples in the literature provide evidence of adaptation, in 
which initial elevations in liver enzymes following initiation of drug therapy return to 
normal after continued drug exposure.289,290 The infrequency and irregularity of DILI 
further complicates our understanding of its pathophysiology, making it difficult to 
predict the risk of DILI in humans. Though mechanisms of DILI remain unclear, 
several hypotheses have been proposed, including the production of reactive 
metabolites, auto-immune responses, or cellular oxidative stress.  All of the 
aforementioned mechanisms are known to alter membrane permeability, resulting in 
perturbation of ATP synthesis.291   
Inhibition of bile acid transport culminating in hepatocellular retention and 
accumulation of bile acids (i.e. cholestasis) also has been proposed as a mechanism 
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of drug-induced liver injury.238,239,292  Mounting evidence in the literature 
demonstrates inhibition of the bile salt export pump (BSEP), the main canalicular 
efflux protein responsible for bile acid excretion, by a number of drugs is associated 
with cholestasis. Currently, potent inhibition of BSEP is considered a potential risk, 
often leading to the termination of a compound during the drug development 
process. One aim of this dissertation research was to utilize the sandwich-cultured 
rat hepatocyte (SCRH) model and freshly isolated suspended rat hepatocytes to 
determine the inhibitory effect of combination protease inhibitors on the hepatic 
transport of bile acids as a mechanism of toxicity (Chapter 2).  A second aim was to 
perform an association study using a candidate-gene approach to elucidate the 
contribution of genetic variants in key bile acid transport and metabolism genes to 
DILI (Chapter 3). 
 
Cellular Viability in Sandwich-Cultured Hepatocytes: Effects of Culture Day 
and Protease Inhibitors.   
In Aim 1, cellular viability assays were conducted to investigate the effect of 
days in culture on drug-mediated cytotoxicity in SCRH (Appendix A), and to 
determine subtoxic protease inhibitor (PI) concentrations for use in subsequent 
studies (Chapter 2).  Lactate dehydrogenase (LDH) and adenosine triphosphate 
(ATP) assays were selected based on work published by Kemp et al. demonstrating 
that the LDH  assay is more sensitive than other conventional assays utilized in 
SCRH (MTT, alamar blue, and propidium iodide staining).248  Additionally, the 
nondestructive nature of the LDH assay allowed multiple studies to be performed on 
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a single sample set.  Quantification of cellular ATP content is also a standard 
approach to determine toxicity and was used to corroborate findings from the LDH 
assay. 
Based on the LDH assay, 24 hour exposure to 100 µM ritonavir (RTV) and 
lopinavir (LPV) yielded significantly lower toxicity on culture day 3 compared to 
culture day 1 (Table A.1).  Next, dose-response studies performed on culture day 3 
demonstrated that RTV and LPV were not toxic at concentrations less than or equal 
to 50 µM; toxicity in these studies was assessed by both LDH and ATP assays.  
Also, both assays revealed that LPV (5-50 µM) combined with RTV (5 µM) did not 
significantly decrease cellular viability compared to LPV alone. As a class, PIs are 
associated with a number of adverse reactions including the production of reactive 
oxygen species, elevated liver function tests, hyperbilirubinemia, jaundice and 
dyslipidemia.293  Based on evidence in the literature, we hypothesized that PIs used 
in combination might exhibit additive hepatotoxic effects compared to single agents.  
However, findings of toxicity studies carried out in SCRH did not support this 
hypothesis.   
In retrospect, determination of protein expression levels of genes implicated 
in the metabolism of LPV, RTV, and bile acids following 24 hour exposure over days 
in culture would have been helpful to interpret the results.  While studies 
characterizing the effects of various culture conditions (e.g. supplemental medium 
content) have been performed to optimize the model, the influence of sustained PI 
exposure on transporters and drug-metabolizing enzymes in sandwich-cultured 
hepatocytes remains unclear.  Understanding the impact of LPV and RTV on 
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metabolic enzymes and transport proteins in SCRH would help determine whether 
there was a shift in the formation of potentially toxic drug or bile acid intermediates 
and/or metabolites.  
  Also, a time-course study evaluating the toxicity of LPV and RTV over 24 
hours, and perhaps beyond, would have proven useful.  Because toxicity was 
evaluated at a single 24-hour time point, we are unable to comment on the effects of 
chronic drug exposure on cellular viability.  It remains unclear how 24-hr incubation 
in vitro corresponds to in vivo exposure.  Thus, it is difficult to extrapolate the present 
results to clinical circumstances.  Nevertheless, the findings of experiments outlined 
in this dissertation work demonstrated that SCRH did not succumb to toxicity using 
PI doses that were within and above the clinically relevant plasma concentrations 
reported in humans.   Recent published data demonstrated bile-acid dependent 
hepatotoxicity of BSEP inhibitors in sandwich-cultured rat hepatocytes.249  
Subsequent studies evaluating the effect of coadministered BSEP inhibitors and bile 
acids on DILI and hepatobiliary bile acid transport are necessary to further clarify the 
mechanisms by which bile acids induce DILI.  
 
Individual and Coadministered Protease Inhibitors Impaired Canalicular 
Excretion of Bile Acids but did not Affect Initial Uptake.  
The purpose of Aim 2 was to investigate the impact of RTV and LPV, alone 
and combined, on the hepatobiliary disposition of the bile acids taurocholate (TCA) 
and chenodeoxycholate (CDCA).  Previous work by McRae and colleagues showed 
that RTV inhibited Bsep-mediated [3H]TCA biliary excretion in SCRH, and to a lesser 
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extent, NTCP-mediated uptake.78  While a small number of studies examining the 
effect of LPV on the initial uptake of bile acid structural analogues have been 
performed, the influence of LPV on [3H]TCA and [14C]CDCA uptake and biliary efflux 
had not been elucidated.  Furthermore, the impact of coadministered PIs (as used 
clinically) on bile acid transport had not been investigated. 
 Studies measuring the effects of LPV and RTV, alone and combined, on 
[3H]TCA and [14C]CDCA accumulation in cells + bile and cells of SCRH were 
performed on culture day 4. Modulation of calcium content in the medium disrupts 
tight junctions causing release of the content of bile canalicular networks permitting 
the accurate determination of cellular substrate concentrations.160,162,245 Co-
incubation (10 min) with LPV, alone and combined with RTV (LPV/r), significantly 
decreased the accumulation of [3H]TCA in cells + bile.  LPV/r significantly increased 
the hepatocellular concentration of [3H]TCA.  While [14C]CDCA accumulation in cells 
+ bile and cells was not significantly altered by LPV and RTV, the biliary clearance of 
[14C]CDCA was ablated by LPV and RTV, alone and combined.  
Initial uptake studies using suspended rat hepatocytes were performed to 
characterize the effect of LPV and RTV on [3H]TCA and [14C]CDCA uptake. Freshly 
isolated suspended hepatocytes are ideal for measuring the initial uptake of 
compounds, however, the utility of suspended hepatocytes is limited due to the rapid 
decrease in cellular viability.  Manipulation of sodium content in the incubation buffer 
allows determination of the contribution of Na+-dependent (Ntcp-driven) and Na+-
independent (Oatp-mediated) transport processes to total uptake.240 Interestingly, 
these studies revealed that the initial uptake rates of [3H]TCA and [14C]CDCA were 
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not affected by LPV and/or RTV at clinically relevant concentrations, suggesting that 
the observed decrease in the biliary excretion of [3H]TCA and [14C]CDCA following 
PI exposure was not due to decreased bile acid uptake. 
 
Protease Inhibitors Decreased Total Endogenous Bile Acid Concentrations in 
Sandwich-cultured Rat Hepatocytes.   
The objective of Aim 3 was to evaluate the effect of LPV and RTV, alone and 
combined, on the accumulation of endogenous bile acids in cells + bile, cells, and 
medium of SCRH.  Hepatocytes were treated with LPV and RTV for 24 hours, 
beginning on day 3. Next, concentrations of endogenous bile acids [TCA, 
taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), 
glycochenodeoxycholic acid (GCDCA), α- and ß-tauromuricholic acid (TMCA)] were 
measured on day 4 by high performance liquid chromatography and mass 
spectrometry. 
 The 10-minute accumulation studies in day 4 SCRH showed potent inhibition 
of [3H]TCA and [14C]CDCA biliary excretion due to LPV and RTV exposure.  
Therefore, culturing hepatocytes with LPV and RTV for 24 hours was expected to 
significantly inhibit the biliary clearance of endogenous bile acids, thereby increasing 
intracellular accumulation of bile acids.  Surprisingly, LPV and RTV treatment 
significantly decreased total bile acid accumulation (the sum of all measured bile 
acids) in cells + bile, cells, and medium of SCRH compared to vehicle control. One 
explanation for these findings is that PI treatment decreased bile acid synthesis.  
Although Zhou and colleagues reported that RTV inhibited CYP7A1, the rate-limiting 
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enzyme in the conversion of cholesterol to bile acids, in a concentration-dependent 
manner, the effect of LPV on bile acid biosynthesis has not been examined. 
Alternatively, the observed decrease in total bile acid accumulation may be 
attributed to increased metabolism of bile acids following PI exposure.  Subsequent 
studies are necessary to determine the impact of PIs on the formation and 
catabolism of endogenous bile acids in SCRH.  It is also plausible that 
compensatory efflux via the basolateral transporters (e.g., MRP3 and/or MRP4) 
played a role in decreased cellular concentrations of bile acids. While it is difficult to 
design and implement basolateral efflux studies in sandwich-cultured hepatocytes, 
future experiments should be conducted to measure the contribution of basolateral 
efflux transporters following PI exposure.  Whole-animal experiments using wild-type 
and Mrp2-deficient rats, in which both renal and hepatic mRNA and protein 
expression of basolateral efflux transporters (e.g. Mrp3 and Mrp4) are evaluated 
following short-term and chronic administration of LPV and RTV, would be novel and 
relevant.  Also, the correlation between drug and bile acid concentrations in the 
plasma and concentrations at target organs remain unclear. Concentrations of PIs, 
cholesterol, bilirubin, and bile acids also could be quantified from serum as well as 
renal and hepatic tissues harvested from these animals. These studies would help 
clarify the relationship between the concentrations of drug and endogenous 
compounds in the serum versus target organs and ultimately aid in better prediction 
of pharmacological outcomes. 
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Role of Genetic Variants in Drug-induced Liver Injury  
Increasing evidence in the literature suggests that single nucleotide 
polymorphisms (SNPs) that alter the function of key enzyme and transporter genes 
influence the pharmacokinetic profile of substrates, including drugs and endogenous 
compounds. Thus, the goal of Aim 4 was to determine the contribution of genetic 
variants in relevant bile acid metabolism and transport genes to the risk of DILI by 
performing an association analysis using a candidate-gene approach.  The 
investigated genes included two canalicular bile acid export transporters: bile salt 
export pump (BSEP) and multidrug resistance associated protein 2 (MRP2).  Using 
cases obtained from the Drug-induced Liver Injury Network (DILIN) and controls 
from the 1958 British Birth Cohort, patients who had experienced DILI were 
compared to controls to determine whether there was an increased risk of DILI in 
persons with SNPs in the genes of interest. 
  Importantly, the rs2919351 variant of OSTß yielded a significantly increased 
odds ratio of 10.1 (p<0.0015) when controls were compared to cholestatic and mixed 
DILI cases.  The odds ratio was notably greater for mixed cases alone (17.6, p=3 X 
10-4).  This novel and exciting finding suggests that a genetic variant in the 
basolateral efflux transporter OSTß may contribute to increased risk of DILI in 
humans.  Replication in a larger cohort is necessary to confirm this association. 
 
Future Directions 
 Throughout the course of this dissertation research, my major advisor often 
optimistically reminded me that “good science” generates more questions than it 
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answers.  The studies presented herein yielded exciting and, at times, unexpected, 
observations. Thus, there are a number of studies that would be logical next-steps in 
the future directions of this research program.  While this work addressed the impact 
of coadministered PIs on bile acid transport, management of HIV infection often 
involves multiple drugs from several classes with distinct mechanisms of action.  
Subsequent studies evaluating the influence of coadministered antiretroviral agents, 
using a cassette-dosing approach, on hepatotoxicity and bile acid disposition is 
warranted. Data generated from these studies would provide insight regarding the 
drug-bile acid interactions between antiretrovirals from numerous drug classes.  This 
knowledge is key to understanding the potential risks associated with highly active 
antiretroviral therapy at both the drug transport and metabolism level.   
Also, LPV and RTV are rapidly and extensively metabolized by CYP450 
enzymes; at least one RTV metabolite is pharmacologically active. Therefore, it 
would be useful to characterize the extent of LPV and RTV metabolism in rat and 
human hepatocytes relative to in vivo. These data would provide substantial 
information about the applicability and precision of in vitro model systems in the 
prediction of drug disposition in vivo, because it is costly and time prohibitive to 
perform extensive pharmacokinetic studies of this nature in humans.  To date, the 
ability of drug-transporter interactions to influence the pharmacokinetic disposition, 
and thus, efficacy, and safety profiles of drugs has only recently gained recognition.  
These studies would allow scientists to more accurately predict the physiological 
consequences of drug-transporter interactions, if any, observed in vitro. 
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 Although some preliminary data examining the effect of antiretrovirals on 
systemic bile acid concentrations in HIV-infected patients has been published, 
findings were inconclusive due to small sample sizes and high interindividual 
variability.79 Consequently, despite the association of PIs with disturbances in lipid 
homeostasis, the association between circulating bile acids and antiretroviral use 
remains unclear.  Future studies investigating the consequences of PIs on bile acid 
concentrations in plasma, urine, and bile from HIV-infected patients compared to 
healthy control subjects should be performed.  These data could be used to develop 
a pharmacokinetic model capable of predicting perturbations in bile acid disposition.  
This information would enable scientists to determine the risk of toxicity associated 
with bile acid disposition in humans.  Importantly, these studies could reveal the 
utility of serum bile acids as a biomarker for DILI, and might help elucidate the 
contribution of HIV-infection itself to alterations in bile acid disposition. 
 One limitation of the present work is that only six major bile acids were 
measured by HPLC-MS/MS.  Bile acid metabolism is complex and tightly controlled 
by several regulatory feedback mechanisms.261,294  Additional studies quantifying 
other bile acids, including more toxic bile acid species such as LCA, DCA, as well as 
sulfate and glucuronide conjugates of the major bile acids in both hepatocytes and in 
plasma after PI exposure should also be carried out.  These findings would be 
necessary to detect drug-mediated shifts in the composition of the bile acid pool. 
Such changes may signal either a hepatoprotective response or drug-induced 
changes in key proteins that regulate bile acid synthesis and/or excretion from the 
hepatocyte.  These comprehensive studies should be conducted in both human and 
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rodent models to delineate species differences because bile acid composition and 
the inhibitory potential of drugs on bile acid metabolism and transport reportedly 
differ across species. Identifying preclinical signals of hepatotoxicity would be an 
important contribution to the development of safer drugs. 
A novel and exciting finding of the current work is the observed decrease in 
bile acid concentrations following 24 hour PI co-incubation with SCRH (Chapter 2).  
Follow-up studies measuring bile acid concentrations over 24 hours, as opposed to 
a single end-point, would provide key information regarding the extent and time 
course of decreased bile acid formation or increased bile acid metabolism.  
Measurement of bile acid precursors, such as cholesterol and its intermediate 
metabolites, and bile acid metabolites would help determine where perturbations 
occur in the bile acid synthesis or catabolism cascade.  Also, quantifying protein 
and/or mRNA expression of key enzymes involved in the classical and alternate 
pathways of cholesterol metabolism, such as cholesterol 7-α hydroxylase (CYP7A1) 
and sterol 27-hydroxylase (CYP27A1) could help to determine whether induction or 
inhibition of metabolic enzymes contribute to the changes in bile acid concentrations.  
 The sandwich-cultured hepatocyte model is a relatively new tool to assess 
hepatic uptake and excretory processes of drugs and endogenous compounds. 
Consequently, additional research is needed to characterize bile acid disposition and 
elucidate new applications of this in vitro system.  For example, cholesterol and bile 
acid content over days in culture, and the effects of daily medium changes on these 
levels, have yet to be determined in sandwich-cultured hepatocytes.  Thus, 
interpretation of studies in SCRH exploring drug effects on endogenous bile acids is 
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limited.  Future work should include comprehensive studies describing the inherent 
characteristics of the sandwich-cultured hepatocyte system with respect to bile acid 
disposition, and how this in vitro model compares to the in vivo situation. 
 As discussed in Chapter 3, the genetic study detected a significant 
association between a single variant in OSTß and an increased risk of DILI.  
Subsequent studies clearly identifying functional consequences of genetic variants 
are required to accurately identify and assess the influence of variants on drug-
induced hepatotoxicity. Evidence correlating genetic polymorphisms with functional 
consequences is marginal.  This limitation confounds our understanding of 
interindividual variability in drug pharmacokinetics, and, consequently, efficacy and 
toxicity.  To date, resources that provide useful, accurate information regarding drug-
transporter interactions due to genetic variants are limited.  Initiatives to address this 
scientific need will develop as the field continues to evolve.   
 In conclusion, the present work has enhanced our understanding of the 
interactions between hepatic transport proteins and coadministered antiretroviral 
drugs, specifically LPV and RTV.  Additionally, this project illustrated the 
consequences of those interactions on bile acid disposition in an in vitro model, and 
highlighted the importance of employing a system capable of retaining in vivo like 
properties.  One key finding is that despite the short-term, potent inhibition of Bsep-
mediated bile acid transport, PIs such as LPV and RTV decrease bile acid 
accumulation when incubated for 24 hours with normal rat hepatocytes cultured in a 
sandwich configuration for 4 days.  This observation may explain the lack of toxicity 
that was observed in SCRH when incubated with clinically relevant concentrations of 
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PIs.  Lastly, the genetic study provided a framework for future hypothesis-driven 
association studies, particularly focused on transport proteins that play a role in the 
disposition of bile acids.  
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APPENDIX 
RAW DATA SUMMARY 
Figure 2.1 Sandwich-cultured rat hepatocyte viability (mean and SEM; % control) 
following 24-hr exposure to LPV or RTV.  Day 3 SCRH were treated with LPV or 
RTV (5-100 µM) for 24 hours. Following incubation, LDH release and cellular ATP 
(B) levels were measured.   
 
Viability (%) 
LDH 
  Lopinavir Ritonavir 
Dose (µM) N1 N2 N3 mean  SEM N1 N2 N3 mean  SEM 
5 98.9 98.1 99.5 98.8 0.4 99.8 100.9 99.6 100.1 0.4 
10 100.0 100.0 98.6 99.5 0.5 100.0 100.0 99.6 99.9 0.1 
25 100.0 99.4 98.1 99.2 0.6 100.0 100.0 99.7 99.9 0.1 
50 100.0 99.6 94.8 98.1 1.7 100.0 99.8 98.0 99.3 0.6 
75 93.8 94.8 87.7 92.1 2.2 96.1 93.9 96.5 95.5 0.8 
100 89.4 87.3 87.3 88.0 0.7 89.6 93.9 91.1 91.5 1.3 
ATP 
  Lopinavir Ritonavir 
Dose (µM) N1 N2 N3 mean  SEM N1 N2 N3 mean  SEM 
5 131.8 84.2 89.2 101.8 15.1 98.2 87.9 90.4 92.1 3.1 
10 117.5 103.6 94.6 105.2 6.6 98.7 71.7 87.4 85.9 7.8 
25 101.7 100.1 102.7 101.5 0.8 91.8 87.6 81.2 86.9 3.1 
50 81.9 118.3 43.8 81.3 21.5 98.8 75.6 83.8 86.0 6.8 
75 71.1 58.7 15.4 48.4 16.9 87.2 61.6 63.5 70.8 8.2 
100 59.1 57.2 10.7 42.3 15.9 67.8 53.9 39.3 53.6 8.2 
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Figure 2.2 Accumulation (mean and SEM; pmol/mg protein), BEI (%) and Clbile 
(ml/min/mg protein) of 3H[TCA] in cells + bile and cells of day 4 SCRH following a 
10-min co-incubation with vehicle control (0.1 % DMSO), RTV (5 µM), and LPV (5 
µM), alone or combined (LPV/r). 
 
  cells + bile cells 
  N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
Vehicle 15.9 19.8 12.3 16.00 2.17 6.0 5.7 3.7 5.13 0.72 
RTV 8.8 16.6 7.8 11.07 2.78 9.3 8.3 6.8 8.13 0.73 
LPV 8.3 14.1 9.3 10.57 1.79 6.0 4.7 4.4 5.03 0.49 
LPV/r 8.3 9.2 5.3 7.60 1.18 7.5 7.7 7.9 7.70 0.12 
    
  BEI (%) Clbile (ml/min/kg) 
  N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
Vehicle 62.30 71.21 69.92 67.80 2.78 7.92 11.28 6.88 8.70 1.33 
RTV 0.00 50.00 12.82 20.93 15.00 0.00 6.64 0.80 2.47 2.08 
LPV 27.70 66.67 52.69 49.03 11.41 1.84 7.52 3.92 4.40 1.66 
LPV/r 9.60 16.30 0.00 8.63 4.73 0.64 1.20 0.00 0.60 0.35 
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Figure 2.3 Accumulation (mean and SEM; pmol/mg protein), BEI (%), and Clbile 
(ml/mink/kg) of [14C]CDCA in cells + bile and cells of day 4 SCRH following a 10-min 
co-incubation with vehicle control (0.1% DMSO), RTV (5 µM), and LPV (5 µM), alone 
or combined (LPV/r). 
 
  cells + bile cells 
  N1 N2 N3 mean SEM N1 N2 N3 Mean SEM 
Vehicle 1077.4 793.0 672.2 847.5 120.1 813.3 580.6 515.4 636.4 90.4 
RTV 1026.6 768.7 546.5 780.6 138.7 1115.3 693.3 592.4 800.3 160.2 
LPV 930.9 823.2 456.1 736.7 143.7 812.6 862.1 593.1 755.9 82.7 
LPV/r 1079.4 989.3 558.9 875.9 160.6 1252.7 995.3 542.3 930.1 207.6 
 
  BEI (%) Clbile (ml/min/kg) 
  N1 N2 N3 mean SEM N1 N2 N3 Mean SEM 
Vehicle 30.6 26.8 23.3 26.9 2.1 26.4 21.2 15.7 37.2 8.1 
RTV 0.0 9.8 0.0 3.3 3.3 0.0 7.5 0.0 0.0 0.0 
LPV 12.7 0.0 0.0 4.2 4.2 11.8 0.0 0.0 0.0 0.0 
LPV/r 0.0 0.0 3.0 1.0 1.0 0.0 0.0 1.7 0.0 0.0 
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Figure 2.4. Na+-dependent and Na+-independent uptake of [3H]TCA into freshly isolated suspended rat hepatocytes. 
[3H]TCA accumulation in freshly isolated rat hepatocytes was determined following pre-incubation with vehicle control 
(0.1% DMSO), LPV (10 µM; A) or RTV (5 µM; B), alone and in combination (C), in the presence or absence of sodium. 
 
Control 
  Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 48.24 40.04 42.74 43.67 2.41 12.6 8.56 6.03 9.06 1.91 
30 78.36 66.15 58.39 67.63 5.81 22.37 11.7 5.86 13.31 4.83 
45 92.39 80.86 95.13 89.46 4.37 21.35 11.26 8.44 13.68 3.92 
rate  
(pmol/s/mg p) 1.472 1.361 1.746 1.53 0.04 0.29 0.09 0.08 0.15 0.07 
LPV 
  Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 52.54 38.54 30.83 40.64 6.35 11.78 8.63 6.4 8.94 1.56 
30 78.16 43.46 114.3 78.64 20.45 8.15 12.15 9.89 10.06 1.16 
45 142.45 72.33 127.58 114.12 21.33 16.14 13.26 9.67 13.02 1.87 
rate  
(pmol/s/mg p) 2.997 1.126 3.225 2.45 0.05 0.15 0.15 0.11 0.14 0.04 
RTV 
  Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 56.01 45.87 52.54 51.47 2.98 12 9.11 8.25 9.79 1.13 
30 90.37 61.94 101.98 84.76 11.89 15.69 10.77 11.59 12.68 1.52 
45 92.66 79.03 135.95 102.55 17.16 18.17 14.43 14.02 15.54 1.32 
rate  
(pmol/s/mg p) 1.222 1.105 2.78 1.70 0.30 0.21 0.18 0.19 0.19 0.00 
LPV/r 
  Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 46.82 44.13 21.23 37.39 8.12 13.22 7.11 5.74 8.69 2.30 
30 79.69 84.95 74.58 79.74 2.99 16.06 10.83 8.78 11.89 2.17 
45 97.19 96.23 119.35 104.26 7.55 19.32 9.55 9.78 12.88 3.22 
rate (pmol/s/mg p) 1.679 1.737 3.271 2.23 0.34 0.2 0.08 0.13 0.14 0.04 
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Figure 2.5. Na+-dependent and Na+-independent uptake of [14C]CDCA into freshly isolated suspended rat hepatocytes. 
[14C]CDCA accumulation in freshly isolated rat hepatocytes was determined following pre-incubation with vehicle control 
(0.1% DMSO), LPV (10 µM; A) or RTV (5 µM; B), alone and in combination (C), in the presence or absence of sodium. 
 
Control 
 
Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 374.1 377.5 154.4 302.0 73.8 137.9 248.8 171.3 186.0 32.9 
30 681.7 553.0 223.7 486.2 136.4 315.5 353.9 242.8 304.1 32.6 
45 821.9 679.4 288.6 596.6 159.4 458.2 440.7 264.6 387.9 61.8 
rate (pmol/s/mg p) 14.9 10.1 4.5 9.8 3.0 10.7 6.4 3.1 6.7 2.2 
LPV 
 
Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 471.1 419.0 186.7 359.0 87.4 284.2 195.2 175.1 218.2 33.5 
30 692.6 566.3 302.9 520.6 114.8 372.8 275.6 257.9 302.1 35.7 
45 755.7 642.9 358.4 585.7 118.2 535.0 320.1 310.7 388.6 73.2 
rate (pmol/s/mg p) 9.5 7.5 5.7 7.6 1.1 8.4 4.2 4.5 5.7 1.3 
 
 
RTV 
 
Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 387.4 342.2 189.2 306.3 60.0 332.9 190.4 158.2 227.2 53.7 
30 527.6 464.5 258.1 416.7 81.4 421.5 255.3 191.6 289.5 68.5 
45 597.3 488.6 315.8 467.2 82.0 568.4 298.8 291.5 386.2 91.1 
rate (pmol/s/mg p) 7.0 4.9 4.2 5.4 0.8 7.9 3.6 4.4 5.3 1.3 
LPV/r 
 
Na+-containing buffer Na+-free buffer 
Time (s) N1 N2 N3 Mean SEM N1 N2 N3 mean SEM 
15 627.9 407.5 199.2 411.5 123.8 404.7 204.4 142.1 250.4 79.2 
30 908.5 535.4 302.6 582.2 176.5 640.4 303.2 201.3 381.7 132.7 
45 1094.5 680.3 364.2 713.0 211.5 788.6 383.9 234.2 468.9 165.6 
rate (pmol/s/mg p) 15.6 9.1 5.5 10.0 2.9 12.8 6.0 3.1 7.3 2.9 
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Figure 2.6 Accumulation (pmol/mg protein) of total bile acids (TCA + GCA + TCDCA 
+ GCDCA + α/ß-TMCA) in SCRH (cells, bile, and medium) following 24-h treatment 
with vehicle (0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined.
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 5060 4169 5202 6432 5216 466 
5 µM RTV 3921 2642 3403 4362 3582 369 
5 µM LPV 4866 2605 4109 5162 4185 572 
5 µM LPV + 5 µM RTV 2175 2033 2125 2137 2118 30 
50 µM LPV 2666 1829 2477 2500 2368 185 
50 µM LPV + 5 µM RTV 2015 1409 1979 1669 1768 143 
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Figure 2.7 Accumulation (pmol/mg protein) of endogenous TCA in cells + bile, cells, 
and medium and BEI values in SCRH following 24-h treatment with vehicle (0.1% 
DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined 
 
cells + bile 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 38.17 12.87 74.45 30.48 38.99 12.95 
5 µM RTV 12.80 4.91 39.07 6.61 15.85 7.93 
5 µM LPV 21.70 3.85 45.24 13.39 21.04 8.85 
50 µM LPV 3.65 2.32 18.83 2.63 6.86 4.00 
5 µM LPV+ 
5 µM RTV 2.88 0.60 3.55 0.00 1.76 0.86 
50 µM LPV + 
5 µM RTV 1.06 0.80 6.72 0.92 2.37 1.45 
 
 
 
 
 
cells 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 6.19 3.39 60.19 9.50 19.82 13.51 
5 µM RTV 1.89 1.41 30.21 2.76 9.07 7.05 
5 µM LPV 3.49 1.69 31.13 5.65 10.49 6.93 
50 µM LPV 0.84 0.60 13.07 1.38 3.97 3.04 
5 µM LPV + 
5 µM RTV 0.60 0.20 3.83 0.30 1.23 0.87 
50 µM LPV + 
5 µM RTV 0.83 0.43 5.80 0.79 1.96 1.28 
medium 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 1039.90 512.79 1305.87 1482.57 1085.28 211.40 
5 µM RTV 1309.64 426.00 1062.36 1538.00 1084.00 239.87 
5 µM LPV 1049.84 269.00 1108.77 1225.00 913.15 217.78 
50 µM LPV 601.02 399.00 661.87 961.00 655.72 116.24 
5 µM LPV + 
5 µM RTV 365.12 124.00 310.55 252.00 262.92 51.75 
50 µM LPV + 
5 µM RTV 300.00 140.00 316.68 313.00 267.42 42.62 
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Figure 2.8 Accumulation (pmol/mg protein) of endogenous TCDCA in cells + bile, 
cells, and medium and BEI values in SCRH following 24-h treatment with vehicle 
(0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined 
 
cells + bile 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 8.93 4.02 8.09 11.3 8.09 1.52 
5 µM RTV 1.33 1.20 2.34 1.39 1.57 0.26 
5 µM LPV 10.00 3.59 5.75 10.7 7.50 1.70 
50 µM LPV 0.96 0.00 1.34 1.05 0.84 0.29 
5 µM LPV + 
5 µM RTV 1.14 0.00 1.10 0.00 0.56 0.32 
50 µM LPV + 
5 µM RTV 0.00 0.95 0.93 0.00 0.47 0.27 
cells 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 3.12 2.89 9.30 3.81 4.78 1.52 
5 µM RTV 0.97 1.32 2.68 0.98 1.49 0.41 
5 µM LPV 3.49 2.89 5.94 4.31 4.16 0.66 
50 µM LPV 0.00 0.90 1.32 0.93 0.79 0.28 
5 µM LPV + 
5 µM RTV 0.00 0.61 1.21 0.00 0.46 0.29 
50 µM LPV + 
5 µM RTV 0.30 0.61 1.23 0.00 0.54 0.26 
medium 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 38.96 30.79 10.02 30.26 27.50 6.16 
5 µM RTV 12.50 19.69 1.44 10.82 11.11 3.75 
5 µM LPV 82.38 43.54 15.81 66.51 52.06 14.48 
50 µM LPV 13.08 14.94 0.00 10.86 9.72 3.35 
5 µM LPV + 
5 µM RTV 45.40 28.27 16.15 42.18 33.0 6.74 
50 µM LPV + 
5 µM RTV 33.32 44.48 14.68 73.04 41.38 12.21 
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Figure 2.9 Accumulation (pmol/mg protein) of endogenous α/ß-TMCA in cells + bile, 
cells, and medium and BEI values in SCRH following 24-h treatment with vehicle 
(0.1% DMSO), RTV (5 µM), and LPV (5 or 50 µM), alone or combined 
 
cells + bile 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 899 701 2756 740 1274 496 
5 µM RTV 348 307 1166 172 498 226 
5 µM LPV 404 246 1454 203 577 296 
50 µM LPV 194 153 782 100 307 159 
5 µM LPV + 
5 µM RTV 51 50 234 30 91 48 
50 µM LPV + 
5 µM RTV 52 27 248 27 89 53 
cells 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 478 503 2656 416 1013 548 
5 µM RTV 190 251 1160 122 431 245 
5 µM LPV 219 239 1318 142 480 280 
50 µM LPV 107 115 598 74 224 125 
5 µM LPV + 
5 µM RTV 38 50 239 23 88 51 
50 µM LPV + 
5 µM RTV 42 30 235 25 83 51 
medium 
 
N1 N2 N3 N4 mean SEM 
Vehicle Control 2999 2827 938 3859 2656 615 
5 µM RTV 2173 1818 1074 2294 1840 275 
5 µM LPV 3257 2003 1409 3372 2510 480 
50 µM LPV 1560 1723 996 1701 1495 170 
5 µM LPV + 
5 µM RTV 1975 1305 1526 1302 1527 158 
50 µM LPV + 
5 µM RTV 1629 1185 1378 1215 1352 102 
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Table A.1 Toxicity (%) after 24 hour drug exposure.  LDH release was measured in 
sandwich-cultured rat hepatocytes after 24 hour incubation with 100 µM LPV, RTV, 
triclosan (TCS), or vehicle (0.1 DMSO) beginning on day 1, 2, or 3 in culture.  
  N  Day Toxicity (%) AVG SEM 
RTV 
1 day 1 37.010 60.16 12.21068 
2 day 1 78.470     
3 day 1 65.000     
1 day 2 14.720 20.24 9.149541 
2 day 2 7.891     
3 day 2 38.110     
1 day 3 1.500 6.39 2.477707 
2 day 3 9.530     
3 day 3 8.140     
LPV 
1 day 1 98.670 96.69 2.672719 
2 day 1 100.000     
3 day 1 91.400     
1 day 2 56.180 49.75 13.1825 
2 day 2 24.400     
3 day 2 68.680     
1 day 3 36.540 38.55 16.63488 
2 day 3 10.790     
3 day 3 68.310     
TCS 
1 day 1 95.900 97.30 1.350308 
2 day 1 100.000     
3 day 1 96.000     
1 day 2 90.210 88.66 1.348833 
2 day 2 89.790     
3 day 2 85.970     
1 day 3 83.660 72.48 9.886085 
2 day 3 52.770     
3 day 3 81.020     
Vehicle 
1 day 1 2.708 0.685 1.029 
2 day 1 0.000     
3 day 1 -0.652     
1 day 2 0.504 0.40 0.21065 
2 day 2 0.000     
3 day 2 0.709     
1 day 3 0.106 -0.026 0.258237 
2 day 3 0.341     
3 day 3 -0.524     
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